



AJOONI BIOTECH LIMITED

Regd. Office: D-118, Industrial Area, Phase VII, Mohali-160055 (Pb.)

Corp Office: H.No 1769, Phase 3B2, Mohali-160059

Phone: 0172-5020758-69 Website: www.ajoonibiotech.com

E-mail: ajooni.biotech@gmail.com / info@ajoonibiotech.com

CIN: L85190PB2010PLC040162

August 29, 2025

To,
National Stock Exchange of India Ltd
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400051

Dear Sir / Madam,

SYMBOL: AJOONI

Subject: Intimation of Notice of the 15th Annual General Meeting for the financial year ended 31st March, 2025 through Video Conferencing

Ref: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed Notice along with Explanatory Statement of the 15th Annual General Meeting of the Company for the financial year ended 31st March, 2025 to be held on Monday, 29th day of September 2025, through Video Conferencing/ Other Audio Visual Means in compliance with the circulars issued by the Ministry of Corporate Affairs ('MCA'), Government of India and Securities and Exchange Board of India ('SEBI') and all other applicable laws.

Kindly take the same on your records.

Thanking You,
Yours Truly,

For, AJOONI BIOTECH LIMITED

Swati Vijan
Company Secretary
FCS13627

Enclo: As Above

AJOONI BIOTECH LIMITED

Registered office: D-118, Industrial Area, Phase VII, Mohali, Punjab-160059

Corporate Office : House NO. 1769, Phase 3B2, Mohali, Punjab-160055

CIN: L85190PB2010PLC040162; E-mail: ajooni118@gmail.com/cs@ajoonibiotech.com/

info@ajoonibiotech.com , Website: <https://ajoonibiotech.com>

NOTICE OF 15TH ANNUAL GENERAL MEETING

NOTICE IS HEREBY GIVEN THAT THE 15TH ANNUAL GENERAL MEETING ('AGM') OF THE SHAREHOLDERS OF AJOONI BIOTECH LIMITED ('THE COMPANY') WILL BE HELD ON MONDAY, 29TH DAY OF SEPTEMBER, 2025, AT 11.00 A.M. THROUGH VIDEO CONFERENCING ('VC')/ OTHER AUDIO-VISUAL MEANS (OAVM) FACILITY TO TRANSACT THE FOLLOWING BUSINESS:

ORDINARY BUSINESS:

1. To receive, consider and adopt the Audited Financial Statements of the Company for the Financial Year ended 31st March, 2025, together with the Reports of the Board of Directors and Auditors thereon.
2. To re-appoint a Director in place of Mr. Partek Singh (DIN: 07864006) who retires by rotation in terms of Section 152(6) of the Companies Act, 2013 and being eligible, offers himself for re-appointment.

SPECIAL BUSINESS:

3. TO APPROVE RELATED PARTY TRANSACTIONS OF THE COMPANY WITH HEALTHY BIOSCIENCES LIMITED

To consider and if thought fit, to pass, the following resolution as an **Ordinary Resolution**:

"RESOLVED THAT pursuant to the provisions of Section 188 of the Companies Act, 2013 ("Act") and all other applicable provisions, if any, read with Rule 15 of the Companies (Meetings of Board and its Powers) Rules, 2014, as amended till date, and subject to Regulation 23(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") and the company's policy on Related Party transaction(s), also based on the recommendation of the Audit Committee and the Board of Directors, approval of shareholders be and is hereby accorded to enter into agreement(s)/ contract(s)/ arrangement(s)/ transaction(s) with Healthy Biosciences Limited, the related party of the company within the meaning of Section 2(76) of the Companies Act, 2013 and Regulation 2(1)(zb) of the Listing Regulations for a cumulative value not exceeding Rs. 6 Crores (Rupees Six Crores only) per financial year for a period of three (3) financial years starting from FY 2025-26 to FY 2027-28, with relation to purchase or supply of goods or materials, selling or otherwise disposing of, or buying, property of any kind, leasing of property of any kind, availing or rendering of any services, reimbursement of expenses, appointment of agent for purchase or sale of goods or any, taking/giving inter-corporate loans/advances, selling/disposing/buying/leasing property of any kind, payment of dividend on investment in securities, materials services or property or appointment of such parties to any office or place of profit in the company, or its subsidiary or associate company or any other transactions of whatever nature, (hereinafter collectively referred to as 'related party transactions') on such terms and conditions as the Board of Directors may deem fit, provided that the said contract(s)/ arrangement(s)/transaction(s) so carried out shall be at arm's length basis and in the ordinary course of business of the Company.

RESOLVED FURTHER THAT the Board of Directors of the Company be and is hereby authorized to settle any question, difficulty or doubt that may arise and to undertake all such acts, deeds, matters and things to finalize and execute such documents, deeds, agreements, arrangements and writings as may be deemed necessary, proper and desirable in its absolute discretion to give effect to the aforesaid Resolution.

RESOLVED FURTHER THAT the Board of Directors be and is hereby authorized to delegate all or any of the powers conferred on it by or under this resolution to any Committee of Directors of the company and to do all acts and take such steps as may be considered necessary or expedient to give effect to the aforesaid resolution.”

4. TO APPROVE RELATED PARTY TRANSACTIONS OF THE COMPANY WITH PUNJAB BIOTECHNOLOGY PARK LIMITED

To consider and if thought fit, to pass, the following Resolution as an **Ordinary Resolution**:

“**RESOLVED THAT** pursuant to the provisions of Section 188 of the Companies Act, 2013 (“Act”) and all other applicable provisions, if any, read with Rule 15 of the Companies (Meetings of Board and its Powers) Rules, 2014, as amended till date, and subject to Regulation 23(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) and the company’s policy on Related Party transaction(s), also based on the recommendation of the Audit Committee and the Board of Directors, approval of shareholders be and is hereby accorded to enter into agreement(s)/ contract(s)/ arrangement(s)/ transaction(s) with Punjab Biotechnology Park Limited, the related party of the company within the meaning of Section 2(76) of the Companies Act, 2013 and Regulation 2(1)(zb) of the Listing Regulations for a cumulative value not exceeding Rs. 7 Crores (Rupees Seven Crores only) per financial year for a period of three (3) financial years starting from FY 2025-26 to FY 2027-28, with relation to purchase or supply of goods or materials, selling or otherwise disposing of, or buying, property of any kind, leasing of property of any kind, availing or rendering of any services, reimbursement of expenses, appointment of agent for purchase or sale of goods or any, taking/giving inter-corporate loans/advances, selling/disposing/buying/leasing property of any kind, payment of dividend on investment in securities, materials services or property or appointment of such parties to any office or place of profit in the company, or its subsidiary or associate company or any other transactions of whatever nature, (hereinafter collectively referred to as 'related party transactions') on such terms and conditions as the Board of Directors may deem fit, provided that the said contract(s)/ arrangement(s)/transaction(s) so carried out shall be at arm’s length basis and in the ordinary course of business of the Company.

RESOLVED FURTHER THAT the Board of Directors of the Company be and is hereby authorized to settle any question, difficulty or doubt that may arise and to undertake all such acts, deeds, matters and things to finalize and execute such documents, deeds, agreements, arrangements and writings as may be deemed necessary, proper and desirable in its absolute discretion to give effect to the aforesaid Resolution.

RESOLVED FURTHER THAT the Board of Directors be and is hereby authorized to delegate all or any of the powers conferred on it by or under this resolution to any Committee of Directors of the company and to do all acts and take such steps as may be considered necessary or expedient to give effect to the aforesaid resolution.”

5. TO APPROVE RELATED PARTY TRANSACTIONS OF THE COMPANY WITH GILBERT KASALI PRIVATE LIMITED

To consider and if thought fit, to pass, the following Resolution as an **Ordinary Resolution**:

“RESOLVED THAT pursuant to the provisions of Section 188 of the Companies Act, 2013 (“Act”) and all other applicable provisions, if any, read with Rule 15 of the Companies (Meetings of Board and its Powers) Rules, 2014, as amended till date, and subject to Regulation 23(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) and the company’s policy on Related Party transaction(s), also based on the recommendation of the Audit Committee and the Board of Directors, approval of shareholders be and is hereby accorded to enter into agreement(s)/ contract(s)/ arrangement(s)/ transaction(s) with Gilbert Kasali Private Limited, the related party of the company within the meaning of Section 2(76) of the Companies Act, 2013 and Regulation 2(1)(zb) of the Listing Regulations for a cumulative value not exceeding Rs. 40 lakhs (Rupees Forty Lakhs only) per financial year for a period of three (3) financial years starting from FY 2025-26 to FY 2027-28, with relation to purchase or supply of goods or materials, selling or otherwise disposing of, or buying, property of any kind, leasing of property of any kind, availing or rendering of any services, reimbursement of expenses, appointment of agent for purchase or sale of goods or any, taking/giving inter-corporate loans/advances, selling/disposing/buying/leasing property of any kind, payment of dividend on investment in securities, materials services or property or appointment of such parties to any office or place of profit in the company, or its subsidiary or associate company or any other transactions of whatever nature, (hereinafter collectively referred to as 'related party transactions') on such terms and conditions as the Board of Directors may deem fit, provided that the said contract(s)/ arrangement(s)/transaction(s) so carried out shall be at arm’s length basis and in the ordinary course of business of the Company.

RESOLVED FURTHER THAT the Board of Directors of the Company be and is hereby authorized to settle any question, difficulty or doubt that may arise and to undertake all such acts, deeds, matters and things to finalize and execute such documents, deeds, agreements, arrangements and writings as may be deemed necessary, proper and desirable in its absolute discretion to give effect to the aforesaid Resolution.

RESOLVED FURTHER THAT the Board of Directors be and is hereby authorized to delegate all or any of the powers conferred on it by or under this resolution to any Committee of Directors of the company and to do all acts and take such steps as may be considered necessary or expedient to give effect to the aforesaid resolution.”

6. TO APPROVE RELATED PARTY TRANSACTIONS OF THE COMPANY WITH REVIVE AESTHETICS PRIVATE LIMITED

To consider and if thought fit, to pass, the following Resolution as an **Ordinary Resolution**:

“RESOLVED THAT pursuant to the provisions of Section 188 of the Companies Act, 2013 (“Act”) and all other applicable provisions, if any, read with Rule 15 of the Companies (Meetings of Board and its Powers) Rules, 2014, as amended till date, and subject to Regulation 23(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) and the company’s policy on Related Party transaction(s), also based on the recommendation of the Audit Committee and the Board of Directors, approval of shareholders be and is hereby accorded to enter into agreement(s)/

contract(s)/ arrangement(s)/ transaction(s) with Revive Aesthetics Private Limited, the related party of the company within the meaning of Section 2(76) of the Companies Act, 2013 and Regulation 2(1)(zb) of the Listing Regulations for a cumulative value not exceeding Rs. 50 lakhs (Rupees Fifty Lakhs only) per financial year for a period of three (3) financial years starting from FY 2025-26 to FY 2027-28, with relation to purchase or supply of goods or materials, selling or otherwise disposing of, or buying, property of any kind, leasing of property of any kind, availing or rendering of any services, reimbursement of expenses, appointment of agent for purchase or sale of goods or any, taking/giving inter-corporate loans/advances, selling/disposing/buying/leasing property of any kind, payment of dividend on investment in securities, materials services or property or appointment of such parties to any office or place of profit in the company, or its subsidiary or associate company or any other transactions of whatever nature, (hereinafter collectively referred to as 'related party transactions') on such terms and conditions as the Board of Directors may deem fit, provided that the said contract(s)/ arrangement(s)/transaction(s) so carried out shall be at arm's length basis and in the ordinary course of business of the Company.

RESOLVED FURTHER THAT the Board of Directors of the Company be and is hereby authorized to settle any question, difficulty or doubt that may arise and to undertake all such acts, deeds, matters and things to finalize and execute such documents, deeds, agreements, arrangements and writings as may be deemed necessary, proper and desirable in its absolute discretion to give effect to the aforesaid Resolution.

RESOLVED FURTHER THAT the Board of Directors be and is hereby authorized to delegate all or any of the powers conferred on it by or under this resolution to any Committee of Directors of the company and to do all acts and take such steps as may be considered necessary or expedient to give effect to the aforesaid resolution."

7. TO APPROVE RELATED PARTY TRANSACTIONS OF THE COMPANY WITH M/S. KHANNA SOLVEX

To consider and if thought fit, to pass, the following Resolution as an **Ordinary Resolution**:

"RESOLVED THAT pursuant to the provisions of Section 188 of the Companies Act, 2013 ("Act") and all other applicable provisions, if any, read with Rule 15 of the Companies (Meetings of Board and its Powers) Rules, 2014, as amended till date, and subject to Regulation 23(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") and the company's policy on Related Party transaction(s), also based on the recommendation of the Audit Committee and the Board of Directors, approval of shareholders be and is hereby accorded to enter into agreement(s)/ contract(s)/ arrangement(s)/ transaction(s) with M/s Khanna Solvex (Partnership Firm), the related party of the company within the meaning of Section 2(76) of the Companies Act, 2013 and Regulation 2(1)(zb) of the Listing Regulations for a cumulative value not exceeding Rs. 5.50 Crores (Rupees Five Crores Fifty Lakhs only) per financial year for a period of three (3) financial years starting from FY 2025-26 to FY 2027-28, with relation to purchase or supply of goods or materials, selling or otherwise disposing of, or buying, property of any kind, leasing of property of any kind, availing or rendering of any services, reimbursement of expenses, appointment of agent for purchase or sale of goods or any, taking/giving inter-corporate loans/advances, selling/disposing/buying/leasing property of any kind, payment of dividend on investment in securities, materials services or property or appointment of such parties to any office or place of profit in the company, or its subsidiary or associate company or any other transactions of whatever nature, (hereinafter collectively referred to as 'related party transactions') on such terms and conditions as the Board of Directors may deem

fit, provided that the said contract(s)/ arrangement(s)/transaction(s) so carried out shall be at arm's length basis and in the ordinary course of business of the Company.

RESOLVED FURTHER THAT the Board of Directors of the Company be and is hereby authorized to settle any question, difficulty or doubt that may arise and to undertake all such acts, deeds, matters and things to finalize and execute such documents, deeds, agreements, arrangements and writings as may be deemed necessary, proper and desirable in its absolute discretion to give effect to the aforesaid Resolution.

RESOLVED FURTHER THAT the Board of Directors be and is hereby authorized to delegate all or any of the powers conferred on it by or under this resolution to any Committee of Directors of the company and to do all acts and take such steps as may be considered necessary or expedient to give effect to the aforesaid resolution."

8. TO CONSIDER APPOINTMENT OF M/S. SDK & ASSOCIATES, PRACTICING COMPANY SECRETARIES AS THE SECRETARIAL AUDITORS OF THE COMPANY FOR FIVE FINANCIAL YEARS FROM FY 2025-26 TO FY 2029-30.

To consider and if thought fit, to pass, the following Resolution as an **Ordinary Resolution**.

"RESOLVED THAT pursuant to the provision of Section 204 of the Companies Act, 2013, read with Rule 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (including any statutory modification(s), enactment(s) or re-enactment(s) thereof, for the time being in force) the consent of the members be and is hereby accorded for the appointment of M/s. SDK & Associates, a peer reviewed firm of Practicing Company Secretaries (Peer Review Certificate no. 7065/2025) as the Secretarial Auditors of the Company for a term of five consecutive financial years commencing from FY 2025-26 to FY 2029-30, on such remuneration to be decided by Managing Director(s)/ CFO/Company Secretary in consultation with Secretarial Auditor from time to time.

RESOLVED FURTHER THAT approval of the members be and is hereby accorded to the Board to avail or obtain from the Secretarial Auditor, such other services or certificates, reports, or opinion which the Secretarial Auditors may be eligible to provide or issue under the applicable laws on such remuneration to be decided by Managing Director(s)/ CFO/Company Secretary in consultation with Secretarial Auditor from time to time.

RESOLVED FURTHER THAT the Board of Directors of the Company be and are hereby authorized to do all such acts, deeds, matters and things as may be considered necessary, desirable or expedient to give effect to this resolution."

9. TO KEEP REGISTERS AND RETURNS AT THE CORPORATE OFFICE OF THE COMPANY

To consider and if thought fit, to pass, the following Resolution as a **Special Resolution**:

"RESOLVED THAT pursuant to the provisions of Section 94 and other applicable provisions, if any, of the Companies Act, 2013 and the rules framed thereunder, including any amendments thereto for the time being in force, the Statutory Registers, records required to be maintained by the Company under Section 88

and the returns required to be filed under Section 92 of the Companies Act, 2013, be kept and maintained at the Company's Corporate Office Situated at House Number 1769, Phase 3B2, S.A.S. Nagar, Mohali-160059, Punjab w.e.f September 30, 2025."

"RESOLVED FURTHER THAT the Board of Directors of the Company be and is hereby authorized for and on behalf of the Company to take all necessary steps and to do all such acts, deeds, matters and things which may deem necessary in this behalf."

10. TO APPROVE REMUNERATION OF MR. GURMEET SINGH FOR HOLDING AN OFFICE OR PLACE OF PROFIT IN THE COMPANY

To consider and if thought fit, to pass, the following Resolution as an **Ordinary Resolution**:

"RESOLVED THAT pursuant to the provisions of Section 188(1)(f) and all other applicable provisions of the Companies Act, 2013 read with Rule 15 of the Companies (Meetings of Board and its Powers) Rules, 2014 (including any statutory modifications or re-enactment thereof, for the time being in force), and Regulation 23 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as per the recommendation and approval of the Nomination and Remuneration Committee and Audit Committee, the consent and approval of the members of the Company be and is hereby accorded to pay remuneration to Mr. Gurmeet Singh (Father of Mr. Jasjot Singh, Managing Director of the Company) being related party and holding an office or place of profit in the Company, as computed under applicable provisions of Companies Act, 2013 at a monthly remuneration not exceeding Rs. 5,00,000 (Rupees Five Lakhs only) per month effective from April 01, 2025 and such other perquisites in accordance with the Act."

"RESOLVED FURTHER THAT the Board of directors of the Company be and is hereby authorized to do, all such acts, matters, deeds and things as may be considered necessary, proper or expedient to give effect to this resolution and matters connected herewith or incidental there to in the best interest of the Company."

11. TO RE-APPOINT MR. GURSIMRAN SINGH (DIN: 02209675) AS A WHOLE TIME DIRECTOR OF THE COMPANY AND FIX HIS REMUNERATION

To consider and if thought fit, to pass, the following Resolution as a **Special Resolution**:

"RESOLVED THAT pursuant to the provisions of Sections 2(78), 2(94), 196, 197, 198 and 203 read with Schedule V and all other applicable provisions of the Companies Act, 2013 and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 (including any statutory modification or re-enactment(s) thereof for the time being in force), Articles of Association of the company as amended from time to time, Regulation 17(6)(e) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and as recommended by the Nomination and Remuneration Committee and Board of Directors, the consent and approval of the members of the company be and is hereby accorded to re-appoint Mr. Gursimran Singh as a Whole Time Director of the company, for a period of five years with effect from 14th August, 2025, whose office is liable to retire by rotation, at a monthly remuneration of upto Rs. 2,00,000/- on the terms and conditions including remuneration as set out in the explanatory statement annexed to the Notice convening this meeting, with liberty to the Board of Directors

to alter and vary the terms and conditions of the said re-appointment including remuneration in such manner as may be agreed between the Board of Directors and Mr. Gursimran Singh.

“RESOLVED FURTHER THAT the Board of Directors of the company be and is hereby authorised to do all acts and take all such steps as may be necessary, proper or expedient to give effect to this resolution.”

12.TO RE-APPOINT MR. JASJOT SINGH (DIN: 01937631) AS A MANAGING DIRECTOR OF THE COMPANY AND INCREASE IN REMUNERATION

To consider and if thought fit, to pass, the following Resolution as a **Special Resolution**:

"RESOLVED THAT pursuant to provision of Section 2(54), 2(78), 196, 197, 198 and 203 read with Schedule V and all other applicable provisions of the Companies Act 2013 and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 (including any statutory modification or re-enactment(s) thereof for the time being in force), Articles of Association of the company as amended from time to time, Regulation 17(6)(e) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and as recommended by the Nomination and Remuneration Committee and Board of Directors, the consent and approval of the members of the company be and is hereby accorded to re-appoint Mr. Jasjot Singh as a Managing Director for a period of five years and revise his remuneration not exceeding Rs. 4,00,000 per month with effect from 01st April, 2025, on the terms and conditions including remuneration asset out in the explanatory statement annexed to the Notice convening this meeting, with liberty to the Board of Directors to alter and vary the terms and conditions of the said re-appointment including remuneration in such manner as may be agreed between the Board of Directors and Mr. Jasjot Singh.

“RESOLVED FURTHER THAT the Board of Directors of the company be and is hereby authorised to do all acts and take all such steps as may be necessary, proper or expedient to give effect to this resolution.”

13.TO APPROVE THE ADVANCEMENT OF LOANS, GUARANTEE OR SECURITY TO ANY PERSON IN WHOM ANY OF THE DIRECTOR OF THE COMPANY IS INTERESTED UNDER SECTION 185 OF COMPANIES ACT, 2013

To consider and if thought fit, to pass, the following Resolution as a **Special Resolution**:

“RESOLVED THAT pursuant to the provisions of Section 185 and other applicable provisions, if any of the Companies Act, 2013 (“the Act”) (including any statutory modifications or re-enactments thereof for the time being in force) and pursuant to the recommendation of the Audit Committee and subject to such approvals, consents, sanctions and permissions as may be necessary, the consent and approval of the members of the Company be and is hereby accorded to the Board of Directors (hereinafter referred to as “the Board” which term shall be deemed to include any duly constituted Committee thereof) for advancing loan(s) in one or more tranches including loan represented by way of book debt to, and/or giving guarantee(s), and/or providing security(ies) in connection with any loan taken/to be taken by any company(ies) which are group companies, associate companies, joint venture companies or subsidiary companies of the Company or any other person in which any of the Directors of the Company is interested as specified in the explanation to section 185(2) of the Act, the details of which are given in the explanatory statement annexed herewith, upto an aggregate amount not exceeding Rs. 55 Crores (Rupees Fifty Five Crores only).”

“RESOLVED FURTHER THAT for the purpose of giving effect to this resolution the Board of the Company be and is hereby authorized to do all acts, deeds and things in their absolute discretion that may be considered necessary, proper and expedient or incidental for the purpose of giving effect to this resolution in the interest of the Company.”

14.TO APPROVE INVESTMENT/ GIVING ANY LOAN OR GUARANTEE/ PROVIDING SECURITY UNDER SECTION 186 OF COMPANIES ACT, 2013

To consider and if thought fit, to pass, the following Resolution as a **Special Resolution**:

“RESOLVED THAT pursuant to the provisions of Section 186 of the Companies Act, 2013 (as amended or re-enacted from time to time) read with Rule 11 and 13 the Companies (Meeting of Board and its Powers) Rules, 2014 and pursuant to the recommendation of the Audit Committee and subject to such approvals, consents, sanctions and permissions as may be necessary, the consent and approval of the members of the Company be and is hereby given to the Board of Directors (hereinafter referred to as “the Board” which term shall be deemed to include any duly constituted Committee thereof) to grant loans or make investment or provide security or guarantee for an amount(s) exceeding 60% of paid up capital, free reserves and securities premium account or 100% of free reserves and securities premium account but not exceeding Rs. 55 Crores (Rupees Fifty Five Crores only), on such terms and conditions as may be decided by the Board of Directors from time to time.”

“RESOLVED FURTHER THAT Board of Directors of the Company be and are hereby authorized to take such steps as may be necessary for obtaining approvals (statutory, contractual or otherwise), in relation to the above and to settle all matters arising out of and incidental thereto and sign, execute and file all deeds, applications, documents, writings, forms that may be required, for and on behalf of the Company for the purpose of giving effect to the aforesaid resolution.”

**By Order of the Board of Directors
For Ajooni Biotech Limited**

Date: 29/08/2025

Place: Mohali

**Sd/-
Swati Vijan
F13627
Company Secretary**

EXPLANATORY STATEMENT PURSUANT TO SECTION 102(1) OF THE COMPANIES ACT, 2013

ITEM NO. 3, 4, 5, 6 and 7

To APPROVE FOR RELATED PARTY TRANSACTIONS

Healthy Biosciences Limited, Punjab Biotechnology Park Limited, Gilbert Kasauli Private Limited, Revive Aesthetics Private Limited and M/s Khanna Solvex are 'related party' of the company within the meaning of Section 2(76) of the Companies Act, 2013 and Regulation 2(1)(zb) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations, 2015"), hence the contracts, agreements, arrangements and transactions by Ajooni Biotech Limited with Healthy Biosciences Limited, Punjab Biotechnology Park Limited, Gilbert Kasauli Private Limited, Revive Aesthetics Private Limited and M/s Khanna Solvex fall under the category of a related party transaction of the Company in terms of the provisions of Section 188 of the Companies Act, 2013, rules framed there under and Regulation 23 of the Listing Regulations, 2015.

In accordance with the Explanation to Regulation 23(1) of the Listing Regulations, 2015, a transaction with related party is considered as material, if the transaction(s) to be entered into individually or taken together with previous transactions during a financial year, exceeds ten percent of the annual consolidated turnover of the company as per the last audited financial statements of the company. The Company had entered into Agreement for related party transactions with Healthy Biosciences Limited, Punjab Biotechnology Park Limited, Gilbert Kasauli Private Limited, Revive Aesthetics Private Limited and M/s Khanna Solvex for a period of one year w.e.f. 1st April, 2025.

Further, pursuant to the SEBI Circular No. SEBI/HO/CFD/CFDPoD- 2/P/CIR/2025/18 dated February 14, 2025, the listed companies are required to place minimum information for review of the audit committee and shareholders for approval of RPTs as per the Industrial Standards issued by Industry Standards Forum (ISF). Relevant information pursuant to the Master circular for compliance with the provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 dated November 11, 2024 read with SEBI Circular dated February 14, 2025, are detailed below.

The Audit Committee and the Board of Directors of the Company at their meeting held on August 29, 2025 subject to approval by the members of the company, have approved entering into the related party contracts, agreements, arrangements and transactions for a period of 3 years i.e. from Financial year 2025-26 to Financial year 2027-28 as more particularly described in table below. It is envisaged that considering the threshold limits prescribed under the Listing Regulations, 2015 and the policy on material related party transactions as adopted by the Company, the related party transactions with Healthy Biosciences Limited, Punjab Biotechnology Park Limited, Gilbert Kasauli Private Limited, Revive Aesthetics Private Limited and M/s Khanna Solvex may be classified as material and may require approval of the members.

The key details pursuant to Explanation 3 to 7 to clause 3 of Rule 15 of Companies (Meetings of Board and its Powers) Rules, 2014 are as below:

Item No. 3.

S. No	Particulars	Details
1	Name of the related party	Healthy Biosciences Limited
2	Name of the Director or KMP who is related	Jasjot Singh, Gursimran Singh (Director)
3	Nature of Relationship	Healthy Biosciences Limited falls under the Promoter group of Ajooni Biotech Limited
4	Nature, material terms, monetary value and particulars of contract or arrangements of Services/ transactions	<p>Nature of transactions: Purchase or supply of goods or materials, selling or otherwise disposing of, or buying, property of any kind, leasing of property of any kind, availing or rendering of any services, reimbursement of expenses, appointment of agent for purchase or sale of goods or any, taking/giving inter-corporate loans/advances, selling/ disposing/ buying/ leasing property of any kind, payment of dividend on investment in securities, materials services or property or appointment of such parties to any office or place of profit in the company, or its subsidiary or associate company or any other transactions of whatever nature</p> <p>Duration: Three years (1/04/2025 to 31/03/2028) The cumulative value of all transactions shall not exceed Rs. 6 Crores per year.</p> <p>Terms: Consideration for each of the transactions shall be determined mutually between the parties, depending on the process and product involved and shall be at an arm's length basis considering prevalent market conditions.</p>
5	The manner of determining the pricing and other commercial terms, both included as part of contract and not considered as part of contract	The pricing/ commercial terms will be determined based on the transactions with unrelated parties for similar nature of transaction, if any. The prices/commercial terms will be determined on arm's length basis.
6	Any other information relevant or important for the members to take a decision on the proposed transaction	Mr. Jasjot Singh, Mrs. Parmjeet Kaur, Mrs. Ishneet Kaur, Mrs. Upneet Kaur are common promoters of Ajooni Biotech and Healthy Biosciences Limited.

Relevant information pursuant to the Master circular for compliance with the provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 dated November 11, 2024 read with SEBI Circular dated February 14, 2025, are detailed below

A (1) Basic Details of the Related Party

S.No.	Particulars of the information	Information provided by the management
1	Name of the related party	Healthy Biosciences Limited
2	Country of incorporation of the related party	India
3	Nature of business of the related party	Manufacturing, trading and selling of wide range of Cattle feed and supplements

A (2) Relationship and ownership of the related party

S.No.	Particulars of the information	Information provided by the management
4	Relationship between the listed entity/subsidiary (in case of transaction involving the subsidiary) and the related party.	Entities over which Promoters/KMP along with close member of promoter /KMP exercise significant influence.
5	Shareholding or contribution % or profit & loss sharing % of the listed entity/ subsidiary (in case of transaction involving the subsidiary), whether direct or indirect, in the related party. Explanation: Indirect shareholding shall mean shareholding held through any person, over which the listed entity or subsidiary has control.	Indirect Holding– 46.2%
6	Shareholding of the related party, whether direct or indirect, in the listed entity/subsidiary (in case of transaction involving the subsidiary). Explanation: Indirect shareholding shall mean shareholding held through any person, over which the related party has control. While calculating indirect shareholding, shareholding held by relatives shall also be considered.	Direct Holding- 7.03% Indirect Holding – 19.86%

A (3) Financial performance of the related party

S.No.	Particulars of the information	Information provided by the management
7	Standalone turnover of the related party for each of the last three financial years	FY 2023-2024 – Rs. 1632.18 lakhs FY 2022-2023 – Rs. 497.19 lakhs FY 2021-2022 – Rs. 51.91 lakhs
8	Standalone net worth of the related party for each of the last three financial years	FY 2023-2024 – Rs. 1470.89 lakhs FY 2022-2023 – Rs. 1251.75 lakhs FY 2021-2022 – Rs. 1095.30lakhs
9	Standalone net profits of the related party for each of the last three financial years	FY 2023-2024 – Rs. 118.35 lakhs FY 2022-2023 – Rs. 60.40 lakhs FY 2021-2022 – Rs. 0.89 lakhs

A (4) Details of previous transactions with the related party

S.No.	Particulars of the information	Information provided by the management
10	Total amount of all the transactions undertaken by the listed entity or subsidiary with the related party during each of the last three financial years. Note: Details need to be disclosed separately for listed entity and its subsidiary.	FY 2024-25 Purchases – Rs. 24873055 Rent Paid - Rs. 212400 FY 2023-24 Purchases – Rs. 58343592 Rent Paid - Rs. 212400 Sales- Rs. 39537192 FY 2022-23 Purchases – Rs. 5471650 Rent Paid - Rs. 212400 Sales- Rs. 7787261 Any Amount paid – Rs. 1200000
11	Total amount of all the transactions undertaken by the listed entity or subsidiary with the related party during the current financial year (till the date of approval of the Audit Committee / shareholders).	Rs. 1.5 crores
12	Whether prior approval of Audit Committee has been taken for the above mentioned transactions?	Yes
13	Any default, if any, made by a related party concerning any obligation undertaken by it under a transaction or arrangement entered into with the listed entity or its subsidiary during the last three financial years.	No default made.

A (5) Amount of the proposed transactions (All types of transactions taken together)

S.No.	Particulars of the information	Information provided by the management
14	Total amount of all the proposed transactions being placed for approval in the current meeting	Max value upto Rs. 6 crores per year
15	Whether the proposed transactions taken together with the transactions undertaken with the related party during the current financial year is material RPT in terms of Para 1(1) of these Standards?	No
16	Value of the proposed transactions as a percentage of the listed entity's annual consolidated turnover for the immediately preceding financial year	5.14%

17	Value of the proposed transactions as a percentage of subsidiary's annual standalone turnover for the immediately preceding financial year (in case of a transaction involving the subsidiary, and where the listed entity is not a party to the transaction)	Not applicable
18	Value of the proposed transactions as a percentage of the related party's annual standalone turnover for the immediately preceding financial year.	21.95%

B (1) Basic details of the proposed transaction

(In case of multiple types of proposed transactions, details to be provided separately for each type of the proposed transaction – for example, (i) sale of goods and purchase of goods to be treated as separate transactions; (ii) sale of goods and sale of services to be treated as separate transactions; (iii) giving of loans and giving of guarantee to be treated as separate transactions)

S.No.	Particulars of the information	Information provided by the management
1	Specific type of the proposed transaction (e.g. sale of goods/services, purchase of goods/services, giving loan, borrowing etc.)	Purchase or supply of goods or materials, selling or disposing of, or buying, property of any kind, leasing of property of any kind, availing or rendering of any services, reimbursement of expenses, appointment of agent for purchase or sale of goods or any, taking/giving inter-corporate loans/advances, selling/ disposing/ buying/ leasing property of any kind, payment of dividend on investment in securities, materials services or property or appointment of such parties to any office or place of profit in the company
2	Details of the proposed transaction	<p>Terms and conditions for transaction in ordinary course of business and at arm's length.</p> <p>1.Nature of Transaction – sale/purchase/rent paid/other transaction</p> <p>2.Delivery of Materials – As per Purchase order</p> <p>3.Payment terms – As per Agreement</p> <p>4.Indirect Taxes as applicable</p> <p>5.Currency – INR</p> <p>6.Such other conditions customary to the context of the contract/agreement/ arrangement.</p>
3	Tenure of the proposed transaction (tenure in	15 months (with reference to SEBI circular

	number of years or months to be specified)	no. SEBI/ HO/CFD/CMD1/CIR/P/2022/47)
4	Indicative date / timeline for undertaking the transaction	Approval has been sought on omnibus basis for 15 months
5	Whether omnibus approval is being sought?	Yes
6	Value of the proposed transaction during a financial year. In case approval of the Audit Committee is sought for multi-year contracts, also provide the aggregate value of transactions during the tenure of the contract. If omnibus approval is being sought, the maximum value of a single transaction during a financial year.	Maximum Value: Rs. 6 crores per annum The maximum value of a single transaction is proposed to be Rs. 50 lakhs
7	Whether the RPTs proposed to be entered into are: (i) not prejudicial to the interest of public shareholders, and (ii) going to be carried out on the same terms and conditions as would be applicable to any party who is not a related party	RPTs are not prejudicial to the interest of public shareholders and would be carried out on the same terms and conditions as would be applicable to any party who is not a related party.
8	Provide a clear justification for entering into the RPT, demonstrating how the proposed RPT serves the best interests of the listed entity and its public shareholders.	The proposed RPT is a strategic step that secures cost efficiency, operational stability and growth opportunities for the company. by being at arm's length and fully transparent, it protects the interest of shareholders while enabling the company to achieve its objectives sustainability.
9	Details of the promoter(s)/ director(s) / key managerial personnel of the listed entity who have interest in the transaction, whether directly or indirectly. The details shall be provided, where the shareholding or contribution or % sharing ratio of the promoter(s) or director(s) or KMP in the related party is more than 2%. Explanation: Indirect interest shall mean interest held through any person over which an individual has control including interest held through relatives. a. Name of the director / KMP b. Shareholding of the director / KMP, whether direct or indirect, in the related party	Promoter and Director/ KMP- Jasjot Singh, Promoters- Upneet Kaur, Ishneet Kaur, Parmjeet Kaur and Ashmeet Kaur have interest in this transaction directly or indirectly. Promoters/ Directors/ KMP having more than 2% shareholding Jasjot Singh and Parmjeet Kaur – 19% Parmjeet Kaur- 10.80% Ishneet Kaur – 15.60%
10	Details of shareholding (more than 2%) of the	

	<p>director(s) / key managerial personnel/ partner(s) of the related party, directly or indirectly, in the listed entity.</p> <p>Explanation: Indirect shareholding shall mean shareholding held through any person over which an individual has control including shareholding held through relatives.</p> <p>a. Name of the director / KMP/ partner b. Shareholding of the director / KMP/ partner, whether direct or indirect, in the listed entity⁷⁶</p>	<p>Promoter and Director/ KMP Jasjot Singh – 11.01%</p> <p>Promoters- Parmjeet Kaur- 3.3% Upneet Kaur- 2.54%</p>
11	A copy of the valuation or other external party report, if any, shall be placed before the Audit Committee	Not applicable
12	Other information relevant for decision making.	-

B (2) Additional details for proposed transactions relating to sale, purchase or supply of goods or services or any other similar business transaction

S.No.	Particulars of the information	Information provided by the management
13	Number of bidders / suppliers / vendors / traders / distributors / service providers from whom bids / quotations were received with respect to the proposed transaction along with details of process followed to obtain bids.	No bids or quotations were obtained by Ajooni for this transaction, as it pertains to sales and purchase activities, not procurement. However, these transactions are strategic, commercial prudent and fully aligned with market trends. All the transactions are reviewed by Audit Committee ensuring independence and fairness. Dealing with related party ensures uninterrupted supply of critical inputs, reducing the risks of volatile external markets.
14	Best bid / quotation received. If comparable bids are available, disclose the price and terms offered.	Not applicable
15	Additional cost / potential loss to the listed entity or the subsidiary in transacting with the related party compared to the best bid / quotation received.	Not applicable
16	Where bids were not invited, the fact shall be	Not applicable

	disclosed along with the justification for the same.	
17	Wherever comparable bids are not available, state what is basis to recommend to the Audit Committee that the terms of proposed RPT are beneficial to the shareholders.	Refer point 13 and point 8 above

Item No. 4

S. No	Particulars	Details
1	Name of the related party	Punjab Biotechnology Park Limited
2	Name of the Director or KMP who is related	Nil
3	Nature of Relationship	Mr. Jasjot Singh, Mr. Gurmeet Singh, Mrs. Parmjeet Kaur and Ms. Ashmeet Kaur are the common promoters of Punjab Biotechnology Park Limited and Ajooni Biotech Limited.
4	Nature, material terms, monetary value and particulars of contract or arrangements of Services/ transactions	<p>Nature of transactions: Purchase or supply of goods or materials, selling or otherwise disposing of, or buying, property of any kind, leasing of property of any kind, availing or rendering of any services, reimbursement of expenses, appointment of agent for purchase or sale of goods or any, taking/giving inter-corporate loans/advances, selling/ disposing/ buying/ leasing property of any kind, payment of dividend on investment in securities, materials services or property or appointment of such parties to any office or place of profit in the company, or its subsidiary or associate company or any other transactions of whatever nature</p> <p>Duration: Three years (1/04/2025 to 31/03/2028) The cumulative value of all transactions shall not exceed Rs. 7 Crores per year.</p> <p>Terms: Consideration for each of the transactions shall be determined mutually between the parties, depending on the process and product involved and shall be at an arm's length basis considering prevalent market conditions.</p>
5	The manner of determining the pricing and other commercial terms, both included as part of contract and not considered as part of contract	The pricing/ commercial terms will be determined based on the transactions with unrelated parties for similar nature of transaction, if any. The prices/commercial terms will be determined on arm's length basis.
6	Any other information relevant or important for the members to take a decision on the proposed	Mr. Jasjot Singh, Mr. Gurmeet Singh, Mrs. Parmjeet Kaur and Ms. Ashmeet Kaur are the common promoters of Punjab Biotechnology Park Limited and Ajooni Biotech Limited.

	transaction	
--	-------------	--

Relevant information pursuant to the Master circular for compliance with the provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 dated November 11, 2024 read with SEBI Circular dated February 14, 2025, are detailed below

A (1) Basic Details of the Related Party

S.No.	Particulars of the information	Information provided by the management
1	Name of the related party	Punjab Biotechnology Park Limited
2	Country of incorporation of the related party	India
3	Nature of business of the related party	Whole sale and retail trading and selling of Cattle feed and supplements

A (2) Relationship and ownership of the related party

S.No.	Particulars of the information	Information provided by the management
4	Relationship between the listed entity/subsidiary (in case of transaction involving the subsidiary) and the related party.	Entities over which Promoters/KMP along with close member of promoter /KMP exercise significant influence.
5	Shareholding or contribution % or profit & loss sharing % of the listed entity/ subsidiary (in case of transaction involving the subsidiary), whether direct or indirect, in the related party. Explanation: Indirect shareholding shall mean shareholding held through any person, over which the listed entity or subsidiary has control.	Indirect Holding – 34.13%
6	Shareholding of the related party, whether direct or indirect, in the listed entity/subsidiary (in case of transaction involving the subsidiary). Explanation: Indirect shareholding shall mean shareholding held through any person, over which the related party has control. While calculating indirect shareholding, shareholding held by relatives shall also be considered.	Direct Holding - 0.26 % Indirect Holding- 26.89%

A (3) Financial performance of the related party

S.No.	Particulars of the information	Information provided by the management
7	Standalone turnover of the related party for each of the last three financial years	FY 2023-2024 – Rs. 294.062 lakhs FY 2022-2023 – Rs. 212.82 lakhs

		FY 2021-2022 – Rs. 23.81 lakhs
8	Standalone net worth of the related party for each of the last three financial years	FY 2023-2024 – Rs. 27.62 lakhs FY 2022-2023 – Rs. (0.52) lakhs FY 2021-2022 – Rs. (21.91) lakhs
9	Standalone net profits of the related party for each of the last three financial years	FY 2023-2024 – Rs. 28.21 lakhs FY 2022-2023 – Rs. 21.40 lakhs FY 2021-2022 – Rs. (71.40) lakhs

A (4) Details of previous transactions with the related party

S.No.	Particulars of the information	Information provided by the management
10	Total amount of all the transactions undertaken by the listed entity or subsidiary with the related party during each of the last three financial years. Note: Details need to be disclosed separately for listed entity and its subsidiary.	FY 2024-25 Amount received – Rs. 1,30,00,000 Payments made - Rs. 4,89,11,000 FY 2023-24 Amount received – Rs. 45,40,000 Payments made - Rs. 33,90,000 Rent Paid - Rs. 4,40,000 FY 2022-23 Purchases – Rs. 54,93,706 Payments made- Rs.70,25,000
11	Total amount of all the transactions undertaken by the listed entity or subsidiary with the related party during the current financial year (till the date of approval of the Audit Committee / shareholders).	Rs. 4.4 crore
12	Whether prior approval of Audit Committee has been taken for the above mentioned transactions?	Yes
13	Any default, if any, made by a related party concerning any obligation undertaken by it under a transaction or arrangement entered into with the listed entity or its subsidiary during the last three financial years.	No default made.

A (5) Amount of the proposed transactions (All types of transactions taken together)

S.No.	Particulars of the information	Information provided by the management
14	Total amount of all the proposed transactions being placed for approval in the current meeting	Max value upto Rs. 7 crores per annum
15	Whether the proposed transactions taken together with the transactions undertaken with the related	No

	party during the current financial year is material RPT in terms of Para 1(1) of these Standards?	
16	Value of the proposed transactions as a percentage of the listed entity's annual consolidated turnover for the immediately preceding financial year	6%
17	Value of the proposed transactions as a percentage of subsidiary's annual standalone turnover for the immediately preceding financial year (in case of a transaction involving the subsidiary, and where the listed entity is not a party to the transaction)	Not applicable
18	Value of the proposed transactions as a percentage of the related party's annual standalone turnover for the immediately preceding financial year.	140%

B (1) Basic details of the proposed transaction

(In case of multiple types of proposed transactions, details to be provided separately for each type of the proposed transaction – for example, (i) sale of goods and purchase of goods to be treated as separate transactions; (ii) sale of goods and sale of services to be treated as separate transactions; (iii) giving of loans and giving of guarantee to be treated as separate transactions)

S.No.	Particulars of the information	Information provided by the management
1	Specific type of the proposed transaction (e.g. sale of goods/services, purchase of goods/services, giving loan, borrowing etc.)	Purchase or supply of goods or materials, selling or otherwise disposing of, or buying, property of any kind, leasing of property of any kind, availing or rendering of any services, reimbursement of expenses, appointment of agent for purchase or sale of goods or any, taking/giving inter-corporate loans/advances, selling/ disposing/ buying/ leasing property of any kind, payment of dividend on investment in securities, materials services or property or appointment of such parties to any office or place of profit in the company
2	Details of the proposed transaction	<p>Terms and conditions for transaction in ordinary course of business and at arm's length.</p> <p>1.Nature of Transaction – sale/purchase/rent paid/other transaction</p> <p>2.Delivery of Materials – As per Purchase order</p> <p>3.Payment terms – As per Agreement</p> <p>4.Indirect Taxes as applicable</p>

		5.Currency – INR 6.Such other conditions customary to the context of the contract/agreement/ arrangement.
3	Tenure of the proposed transaction (tenure in number of years or months to be specified)	15 months (with reference to SEBI circular no. SEBI/ HO/CFD/CMD1/CIR/P/2022/47)
4	Indicative date / timeline for undertaking the transaction	Approval has been sought on omnibus basis for 15 months
5	Whether omnibus approval is being sought?	Yes
6	Value of the proposed transaction during a financial year. In case approval of the Audit Committee is sought for multi-year contracts, also provide the aggregate value of transactions during the tenure of the contract. If omnibus approval is being sought, the maximum value of a single transaction during a financial year.	Maximum Value: upto Rs. 7 crores per annum The maximum value of a single transaction is proposed to be Rs. 50 lakhs
7	Whether the RPTs proposed to be entered into are: (i) not prejudicial to the interest of public shareholders, and (ii) going to be carried out on the same terms and conditions as would be applicable to any party who is not a related party	RPTs are not prejudicial to the interest of public shareholders and would be carried out on the same terms and conditions as would be applicable to any party who is not a related party.
8	Provide a clear justification for entering into the RPT, demonstrating how the proposed RPT serves the best interests of the listed entity and its public shareholders.	The proposed RPT is a strategic step that secures cost efficiency, operational stability and growth opportunities for the company. by being at arm's length and fully transparent, it protects the interest of shareholders while enabling the company to achieve its objectives sustainability.
9	Details of the promoter(s)/ director(s) / key managerial personnel of the listed entity who have interest in the transaction, whether directly or indirectly. The details shall be provided, where the shareholding or contribution or % sharing ratio of the promoter(s) or director(s) or KMP in the related party is more than 2%. Explanation: Indirect interest shall mean interest held through any person over which an individual has control including interest held through relatives.	Promoter and Director/ KMP- Jasjot Singh, Promoters- Upneet Kaur, Ishneet Kaur, Parmjeet Kaur and Ashmeet Kaur and Healthy Biosciences Limited have interest in this transaction directly or indirectly. Promoters/ Directors/ KMP having more than 2% shareholding Parmjeet Kaur- 2.20%

	<p>a. Name of the director / KMP</p> <p>b. Shareholding of the director / KMP, whether direct or indirect, in the related party</p>	
10	<p>Details of shareholding (more than 2%) of the director(s) / key managerial personnel/ partner(s) of the related party, directly or indirectly, in the listed entity.</p> <p>Explanation: Indirect shareholding shall mean shareholding held through any person over which an individual has control including shareholding held through relatives.</p> <p>a. Name of the director / KMP/ partner</p> <p>b. Shareholding of the director / KMP/ partner, whether direct or indirect, in the listed entity</p>	<p>Promoter and Director Jasjot Singh – 11.01%</p> <p>Promoters- Parmjeet Kaur- 3.3% Healthy Biosciences Limited- 7.03% Upneet Kaur – 2.54%</p>
11	A copy of the valuation or other external party report, if any, shall be placed before the Audit Committee	Not applicable
12	Other information relevant for decision making.	

B (2) Additional details for proposed transactions relating to sale, purchase or supply of goods or services or any other similar business transaction

S.No.	Particulars of the information	Information provided by the management
13	Number of bidders / suppliers / vendors / traders / distributors / service providers from whom bids / quotations were received with respect to the proposed transaction along with details of process followed to obtain bids.	No bids or quotations were obtained by Ajooni for this transaction, as it pertains to sales and purchase activities, not procurement. However, these transactions are strategic, commercial prudent and fully aligned with market trends. All the transactions are reviewed by Audit Committee ensuring independence and fairness. Dealing with related party ensures uninterrupted supply of critical inputs, reducing the risks of volatile external markets.
14	Best bid / quotation received. If comparable bids are available, disclose the price and terms offered.	Not applicable
15	Additional cost / potential loss to the listed entity or the subsidiary in transacting with the related	Not applicable

	party compared to the best bid / quotation received.	
16	Where bids were not invited, the fact shall be disclosed along with the justification for the same.	Not applicable
17	Wherever comparable bids are not available, state what is basis to recommend to the Audit Committee that the terms of proposed RPT are beneficial to the shareholders.	Refer point 13 and point 8 above

Item No. 5

S. No	Particulars	Details
1	Name of the related party	Gilbert Kasauli Private Limited
2	Name of the Director or KMP who is related	Mr. Jasjot Singh, Director
3	Nature of Relationship	Mr. Jasjot Singh, being common Director and Promoter of Gilbert Kasauli Private Limited and Ajooni Biotech Limited.
4	Nature, material terms, monetary value and particulars of contract or arrangements of Services/ transactions	<p>Nature of transactions: Purchase or supply of goods or materials, selling or otherwise disposing of, or buying, property of any kind, leasing of property of any kind, availing or rendering of any services, reimbursement of expenses, appointment of agent for purchase or sale of goods or any, taking/giving inter-corporate loans/advances, selling/ disposing/ buying/ leasing property of any kind, payment of dividend on investment in securities, materials services or property or appointment of such parties to any office or place of profit in the company, or its subsidiary or associate company or any other transactions of whatever nature</p> <p>Duration: Three years (1/04/2025 to 31/03/2028) The cumulative value of all transactions shall not exceed Rs. 40 lakhs per year.</p> <p>Terms: Consideration for each of the transactions shall be determined mutually between the parties, depending on the process and product involved and shall be at an arm's length basis considering prevalent market conditions.</p>
5	The manner of determining the pricing and other commercial terms, both included as part of contract and not considered as	The pricing/ commercial terms will be determined based on the transactions with unrelated parties for similar nature of transaction, if any. The prices/commercial terms will be determined on arm's length basis.

	part of contract	
6	Any other information relevant or important for the members to take a decision on the proposed transaction	Mr. Jasjot Singh, being common Director and Promoter of Gilbert Kasauli Private Limited and Ajooni Biotech Limited.

Relevant information pursuant to the Master circular for compliance with the provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 dated November 11, 2024 read with SEBI Circular dated February 14, 2025, are detailed below

A (1) Basic Details of the Related Party

S.No.	Particulars of the information	Information provided by the management
1	Name of the related party	Gilbert Kasauli Private Limited
2	Country of incorporation of the related party	India
3	Nature of business of the related party	To carry on the business as hoteliers, hotel proprietors, hotel managers and operators, refreshment contractors and caterers, restaurant keepers, refreshment room proprietors, milk and snack bar proprietors, and tavern proprietors, lodging house proprietors.

A (2) Relationship and ownership of the related party

S.No.	Particulars of the information	Information provided by the management
4	Relationship between the listed entity/subsidiary (in case of transaction involving the subsidiary) and the related party.	Entities over which Promoters/KMP along with close member of promoter /KMP exercise significant influence.
5	Shareholding or contribution % or profit & loss sharing % of the listed entity/ subsidiary (in case of transaction involving the subsidiary), whether direct or indirect, in the related party. Explanation: Indirect shareholding shall mean shareholding held through any person, over which the listed entity or subsidiary has control.	Indirect Holding – 33.3%
6	Shareholding of the related party, whether direct or indirect, in the listed entity/subsidiary (in case of transaction involving the subsidiary). Explanation: Indirect shareholding shall mean shareholding held through any person, over which the related party has control. While calculating	Indirect Holding – 26.89%

	indirect shareholding, shareholding held by relatives shall also be considered.	
--	---	--

A (3) Financial performance of the related party

S.No.	Particulars of the information	Information provided by the management
7	Standalone turnover of the related party for each of the last three financial years	FY 2023-2024 – Rs. 0.00 lakhs FY 2022-2023 – NA FY 2021-2022 – NA
8	Standalone net worth of the related party for each of the last three financial years	FY 2023-2024 – Rs. 100.00 lakhs FY 2022-2023 – NA FY 2021-2022 – NA
9	Standalone net profits of the related party for each of the last three financial years	FY 2023-2024 – Rs. 0.00 lakhs FY 2022-2023 – NA FY 2021-2022 – NA

A (4) Details of previous transactions with the related party

S.No.	Particulars of the information	Information provided by the management
10	Total amount of all the transactions undertaken by the listed entity or subsidiary with the related party during each of the last three financial years. Note: Details need to be disclosed separately for listed entity and its subsidiary.	FY 2024-25 NIL FY 2023-24 NIL FY 2022-23 NIL
11	Total amount of all the transactions undertaken by the listed entity or subsidiary with the related party during the current financial year (till the date of approval of the Audit Committee / shareholders).	NIL
12	Whether prior approval of Audit Committee has been taken for the above mentioned transactions?	Yes
13	Any default, if any, made by a related party concerning any obligation undertaken by it under a transaction or arrangement entered into with the listed entity or its subsidiary during the last three financial years.	No default made.

A (5) Amount of the proposed transactions (All types of transactions taken together)

S.No.	Particulars of the information	Information provided by the management
14	Total amount of all the proposed transactions being	Max value upto Rs. 40 lakhs per annum

	placed for approval in the current meeting	
15	Whether the proposed transactions taken together with the transactions undertaken with the related party during the current financial year is material RPT in terms of Para 1(1) of these Standards?	No
16	Value of the proposed transactions as a percentage of the listed entity's annual consolidated turnover for the immediately preceding financial year	0.34%
17	Value of the proposed transactions as a percentage of subsidiary's annual standalone turnover for the immediately preceding financial year (in case of a transaction involving the subsidiary, and where the listed entity is not a party to the transaction)	Not applicable
18	Value of the proposed transactions as a percentage of the related party's annual standalone turnover for the immediately preceding financial year.	0

B (1) Basic details of the proposed transaction

(In case of multiple types of proposed transactions, details to be provided separately for each type of the proposed transaction – for example, (i) sale of goods and purchase of goods to be treated as separate transactions; (ii) sale of goods and sale of services to be treated as separate transactions; (iii) giving of loans and giving of guarantee to be treated as separate transactions)

S.No.	Particulars of the information	Information provided by the management
1	Specific type of the proposed transaction (e.g. sale of goods/services, purchase of goods/services, giving loan, borrowing etc.)	Purchase or supply of goods or materials, selling or otherwise disposing of, or buying, property of any kind, leasing of property of any kind, availing or rendering of any services, reimbursement of expenses, appointment of agent for purchase or sale of goods or any, taking/giving inter-corporate loans/advances, selling/ disposing/ buying/ leasing property of any kind, payment of dividend on investment in securities, materials services or property or appointment of such parties to any office or place of profit in the company
2	Details of the proposed transaction	Terms and conditions for transaction in ordinary course of business and at arm's length. 1.Nature of Transaction – sale/purchase/rent paid/other transaction 2.Delivery of Materials – As per Purchase

		<p>order</p> <p>3.Payment terms – As per Agreement</p> <p>4.Indirect Taxes as applicable</p> <p>5.Currency – INR</p> <p>6.Such other conditions customary to the context of the contract/agreement/arrangement.</p>
3	Tenure of the proposed transaction (tenure in number of years or months to be specified)	15 months (with reference to SEBI circular no. SEBI/ HO/CFD/CMD1/CIR/P/2022/47)
4	Indicative date / timeline for undertaking the transaction	Approval has been sought on omnibus basis for 15 months
5	Whether omnibus approval is being sought?	Yes
6	<p>Value of the proposed transaction during a financial year. In case approval of the Audit Committee is sought for multi-year contracts, also provide the aggregate value of transactions during the tenure of the contract.</p> <p>If omnibus approval is being sought, the maximum value of a single transaction during a financial year.</p>	<p>Maximum Value: 40 lakhs per annum</p> <p>The maximum value of a single transaction is proposed to be Rs. 20 lakhs</p>
7	<p>Whether the RPTs proposed to be entered into are:</p> <p>(i) not prejudicial to the interest of public shareholders, and</p> <p>(ii) going to be carried out on the same terms and conditions as would be applicable to any party who is not a related party</p>	RPTs are not prejudicial to the interest of public shareholders and would be carried out on the same terms and conditions as would be applicable to any party who is not a related party.
8	Provide a clear justification for entering into the RPT, demonstrating how the proposed RPT serves the best interests of the listed entity and its public shareholders.	The proposed RPT is a strategic step that secures cost efficiency, operational stability and growth opportunities for the company. by being at arm's length and fully transparent, it protects the interest of shareholders while enabling the company to achieve its objectives sustainability.
9	<p>Details of the promoter(s)/ director(s) / key managerial personnel of the listed entity who have interest in the transaction, whether directly or indirectly.</p> <p>The details shall be provided, where the shareholding or contribution or % sharing ratio of the promoter(s) or director(s) or KMP in the related party is more than 2%.</p> <p>Explanation: Indirect interest shall mean interest</p>	<p>Promoter and Director/ KMP- Jasjot Singh,</p> <p>Promoters- Upneet Kaur, Ishneet Kaur, Parmjeet Kaur and Ashmeet Kaur and Healthy Biosciences Limited</p> <p>have interest in this transaction directly or indirectly.</p> <p>Promoter and Director/ KMP more than 2</p>

	<p>held through any person over which an individual has control including interest held through relatives.</p> <p>a. Name of the director / KMP b. Shareholding of the director / KMP, whether direct or indirect, in the related party</p>	<p>% shareholding Jasjot Singh – 33.3%</p>
10	<p>Details of shareholding (more than 2%) of the director(s) / key managerial personnel/ partner(s) of the related party, directly or indirectly, in the listed entity. Explanation: Indirect shareholding shall mean shareholding held through any person over which an individual has control including shareholding held through relatives.</p> <p>a. Name of the director / KMP/ partner b. Shareholding of the director / KMP/ partner, whether direct or indirect, in the listed entity</p>	<p>Promoter and Director Jasjot Singh – 11.01%</p> <p>Promoters- Parmjeet Kaur- 3.3% Healthy Biosciences Limited- 7.03% Upneet Kaur – 2.54%</p>
11	A copy of the valuation or other external party report, if any, shall be placed before the Audit Committee	Not applicable
12	Other information relevant for decision making.	

B (2) Additional details for proposed transactions relating to sale, purchase or supply of goods or services or any other similar business transaction

S.No.	Particulars of the information	Information provided by the management
13	Number of bidders / suppliers / vendors / traders / distributors / service providers from whom bids / quotations were received with respect to the proposed transaction along with details of process followed to obtain bids.	No bids or quotations were obtained by Ajooni for this transaction, as it pertains to sales and purchase activities, not procurement. However, these transactions are strategic, commercial prudent and fully aligned with market trends. All the transactions are reviewed by Audit Committee ensuring independence and fairness. Dealing with related party ensures uninterrupted supply of critical inputs, reducing the risks of volatile external markets.
14	Best bid / quotation received.	Not applicable

	If comparable bids are available, disclose the price and terms offered.	
15	Additional cost / potential loss to the listed entity or the subsidiary in transacting with the related party compared to the best bid / quotation received.	Not applicable
16	Where bids were not invited, the fact shall be disclosed along with the justification for the same.	Not applicable
17	Wherever comparable bids are not available, state what is basis to recommend to the Audit Committee that the terms of proposed RPT are beneficial to the shareholders.	Refer point 13 and point 8 above

Item No. 6

S. No	Particulars	Details
1	Name of the related party	Revive Aesthetics Private Limited
2	Name of the Director or KMP who is related	Nil
3	Nature of Relationship	Ms. Upneet Kaur, being common Promoter of Revive Aesthetics Private Limited and Ajooni Biotech Limited.
4	Nature, material terms, monetary value and particulars of contract or arrangements of Services/ transactions	<p>Nature of transactions: Purchase or supply of goods or materials, selling or otherwise disposing of, or buying, property of any kind, leasing of property of any kind, availing or rendering of any services, reimbursement of expenses, appointment of agent for purchase or sale of goods or any, taking/giving inter-corporate loans/advances, selling/ disposing/ buying/ leasing property of any kind, payment of dividend on investment in securities, materials services or property or appointment of such parties to any office or place of profit in the company, or its subsidiary or associate company or any other transactions of whatever nature</p> <p>Duration: Three years (1/04/2025 to 31/03/2028) The cumulative value of all transactions shall not exceed Rs. 50 lakhs per year.</p> <p>Terms: Consideration for each of the transactions shall be determined mutually between the parties, depending on the process and product involved and shall be at an arm's length basis considering prevalent market conditions.</p>

5	The manner of determining the pricing and other commercial terms, both included as part of contract and not considered as part of contract	The pricing/ commercial terms will be determined based on the transactions with unrelated parties for similar nature of transaction, if any. The prices/commercial terms will be determined on arm's length basis.
6	Any other information relevant or important for the members to take a decision on the proposed transaction	Ms. Upneet Kaur, being common Promoter of Revive Aesthetics Private Limited and Ajooni Biotech Limited.

Relevant information pursuant to the Master circular for compliance with the provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 dated November 11, 2024 read with SEBI Circular dated February 14, 2025, are detailed below

A (1) Basic Details of the Related Party

S.No.	Particulars of the information	Information provided by the management
1	Name of the related party	Revive Aesthetics Private Limited
2	Country of incorporation of the related party	India
3	Nature of business of the related party	Manufacturing and trading of all kinds of cosmetics, healthcare products, beauty and skin care products, etc.

A (2) Relationship and ownership of the related party

S.No.	Particulars of the information	Information provided by the management
4	Relationship between the listed entity/subsidiary (in case of transaction involving the subsidiary) and the related party.	Entities over which Promoters/KMP along with close member of promoter /KMP exercise significant influence.
5	Shareholding or contribution % or profit & loss sharing % of the listed entity/ subsidiary (in case of transaction involving the subsidiary), whether direct or indirect, in the related party. Explanation: Indirect shareholding shall mean shareholding held through any person, over which the listed entity or subsidiary has control.	Indirect Holding – 91.70 %
6	Shareholding of the related party, whether direct or indirect, in the listed entity/subsidiary (in case of transaction involving the subsidiary). Explanation: Indirect shareholding shall mean shareholding held through any person, over which the related party has control. While calculating indirect shareholding, shareholding held by relatives shall also be considered.	Indirect Holding – 26.89 %

A (3) Financial performance of the related party

S.No.	Particulars of the information	Information provided by the management
7	Standalone turnover of the related party for each of the last three financial years	Since the company was incorporated on 03rd Sep 2024, so FY 24-25 is the first Financial year for the company to prepare its financial results. Due date for the same is 31st December 2025.
8	Standalone net worth of the related party for each of the last three financial years	Since the company was incorporated on 03rd Sep 2024, so FY 24-25 is the first Financial year for the company to prepare its financial results. Due date for the same is 31st December 2025.
9	Standalone net profits of the related party for each of the last three financial years	Since the company was incorporated on 03rd Sep 2024, so FY 24-25 is the first Financial year for the company to prepare its financial results. Due date for the same is 31st December 2025.

A (4) Details of previous transactions with the related party

S.No.	Particulars of the information	Information provided by the management
10	Total amount of all the transactions undertaken by the listed entity or subsidiary with the related party during each of the last three financial years. Note: Details need to be disclosed separately for listed entity and its subsidiary.	FY 2024-25 Nil FY 2023-24 Nil FY 2022-23 Nil
11	Total amount of all the transactions undertaken by the listed entity or subsidiary with the related party during the current financial year (till the date of approval of the Audit Committee / shareholders).	Nil
12	Whether prior approval of Audit Committee has been taken for the above mentioned transactions?	Yes
13	Any default, if any, made by a related party concerning any obligation undertaken by it under a transaction or arrangement entered into with the listed entity or its subsidiary during the last three financial years.	No default made.

A (5) Amount of the proposed transactions (All types of transactions taken together)

S.No.	Particulars of the information	Information provided by the management
14	Total amount of all the proposed transactions being placed for approval in the current meeting	Max value upto Rs. 50 lakhs per annum
15	Whether the proposed transactions taken together with the transactions undertaken with the related party during the current financial year is material RPT in terms of Para 1(1) of these Standards?	No
16	Value of the proposed transactions as a percentage of the listed entity's annual consolidated turnover for the immediately preceding financial year	0.43%
17	Value of the proposed transactions as a percentage of subsidiary's annual standalone turnover for the immediately preceding financial year (in case of a transaction involving the subsidiary, and where the listed entity is not a party to the transaction)	Not applicable
18	Value of the proposed transactions as a percentage of the related party's annual standalone turnover for the immediately preceding financial year.	0

B (1) Basic details of the proposed transaction

(In case of multiple types of proposed transactions, details to be provided separately for each type of the proposed transaction – for example, (i) sale of goods and purchase of goods to be treated as separate transactions; (ii) sale of goods and sale of services to be treated as separate transactions; (iii) giving of loans and giving of guarantee to be treated as separate transactions)

S.No.	Particulars of the information	Information provided by the management
1	Specific type of the proposed transaction (e.g. sale of goods/services, purchase of goods/services, giving loan, borrowing etc.)	Purchase or supply of goods or materials, selling or otherwise disposing of, or buying, property of any kind, leasing of property of any kind, availing or rendering of any services, reimbursement of expenses, appointment of agent for purchase or sale of goods or any, taking/giving inter- corporate loans/advances, selling/ disposing/ buying/ leasing property of any kind, payment of dividend on investment in securities, materials services or property or appointment of such parties to any office or place of profit in the company
2	Details of the proposed transaction	Terms and conditions for transaction in ordinary course of business and at arm's length.

		1.Nature of Transaction – sale/purchase/rent paid/other transaction 2.Delivery of Materials – As per Purchase order 3.Payment terms – As per Agreement 4.Indirect Taxes as applicable 5.Currency – INR 6.Such other conditions customary to the context of the contract/agreement/ arrangement.
3	Tenure of the proposed transaction (tenure in number of years or months to be specified)	15 months (with reference to SEBI circular no. SEBI/ HO/CFD/CMD1/CIR/P/2022/47)
4	Indicative date / timeline for undertaking the transaction	Approval has been sought on omnibus basis for 15 months
5	Whether omnibus approval is being sought?	Yes
6	Value of the proposed transaction during a financial year. In case approval of the Audit Committee is sought for multi-year contracts, also provide the aggregate value of transactions during the tenure of the contract. If omnibus approval is being sought, the maximum value of a single transaction during a financial year.	Maximum Value: upto Rs. 50 lakhs per annum The maximum value of a single transaction is proposed to be Rs. 20 lakhs
7	Whether the RPTs proposed to be entered into are: (i) not prejudicial to the interest of public shareholders, and (ii) going to be carried out on the same terms and conditions as would be applicable to any party who is not a related party	RPTs are not prejudicial to the interest of public shareholders and would be carried out on the same terms and conditions as would be applicable to any party who is not a related party.
8	Provide a clear justification for entering into the RPT, demonstrating how the proposed RPT serves the best interests of the listed entity and its public shareholders.	The proposed RPT is a strategic step that secures cost efficiency, operational stability and growth opportunities for the company. by being at arm's length and fully transparent, it protects the interest of shareholders while enabling the company to achieve its objectives sustainability.
9	Details of the promoter(s)/ director(s) / key managerial personnel of the listed entity who have interest in the transaction, whether directly or indirectly. The details shall be provided, where the	Promoter and Director/ KMP- Jasjot Singh, Promoters- Upneet Kaur, Ishneet Kaur, Parmjeet Kaur and Ashmeet Kaur and Healthy Biosciences Limited

	<p>shareholding or contribution or % sharing ratio of the promoter(s) or director(s) or KMP in the related party is more than 2%.</p> <p>Explanation: Indirect interest shall mean interest held through any person over which an individual has control including interest held through relatives.</p> <p>a. Name of the director / KMP b. Shareholding of the director / KMP, whether direct or indirect, in the related party</p>	<p>have interest in this transaction directly or indirectly.</p> <p>Promoter more than 2 % shareholding Upneet Kaur – 91.70%</p>
10	<p>Details of shareholding (more than 2%) of the director(s) / key managerial personnel/ partner(s) of the related party, directly or indirectly, in the listed entity.</p> <p>Explanation: Indirect shareholding shall mean shareholding held through any person over which an individual has control including shareholding held through relatives.</p> <p>a. Name of the director / KMP/ partner b. Shareholding of the director / KMP/ partner, whether direct or indirect, in the listed entity</p>	<p>Promoters- Jasjot Singh – 11.01% Parmjeet Kaur- 3.3% Healthy Biosciences Limited- 7.03% Upneet Kaur – 2.54%</p>
11	A copy of the valuation or other external party report, if any, shall be placed before the Audit Committee	Not applicable
12	Other information relevant for decision making.	

B (2) Additional details for proposed transactions relating to sale, purchase or supply of goods or services or any other similar business transaction

S.No.	Particulars of the information	Information provided by the management
13	Number of bidders / suppliers / vendors / traders / distributors / service providers from whom bids / quotations were received with respect to the proposed transaction along with details of process followed to obtain bids.	No bids or quotations were obtained by Ajooni for this transaction, as it pertains to sales and purchase activities, not procurement. However, these transactions are strategic, commercial prudent and fully aligned with market trends. All the transactions are reviewed by Audit Committee ensuring independence and fairness. Dealing with related party ensures uninterrupted supply of critical inputs,

		reducing the risks of volatile external markets.
14	Best bid / quotation received. If comparable bids are available, disclose the price and terms offered.	Not applicable
15	Additional cost / potential loss to the listed entity or the subsidiary in transacting with the related party compared to the best bid / quotation received.	Not applicable
16	Where bids were not invited, the fact shall be disclosed along with the justification for the same.	Not applicable
17	Wherever comparable bids are not available, state what is basis to recommend to the Audit Committee that the terms of proposed RPT are beneficial to the shareholders.	Refer point 13 and point 8 above

Item No. 7

S. No	Particulars	Details
1	Name of the related party	M/s Khanna Solvex (Partnership Firm)
2	Name of the Director or KMP who is related	Mr. Jasjot Singh, Partner in M/s. Khanna Solvex
3	Nature of Relationship	Mr. Jasjot Singh and Mrs. Parmjeet Kaur, being common Promoter of M/s Khanna Solvex and Ajooni Biotech Limited.
4	Nature, material terms, monetary value and particulars of contract or arrangements of Services/ transactions	<p>Nature of transactions: Purchase or supply of goods or materials, selling or otherwise disposing of, or buying, property of any kind, leasing of property of any kind, availing or rendering of any services, reimbursement of expenses, appointment of agent for purchase or sale of goods or any, taking/giving inter-corporate loans/advances, selling/ disposing/ buying/ leasing property of any kind, payment of dividend on investment in securities, materials services or property or appointment of such parties to any office or place of profit in the company, or its subsidiary or associate company or any other transactions of whatever nature</p> <p>Duration: Three years (1/04/2025 to 31/03/2028) The cumulative value of all transactions shall not exceed Rs. 5.50 Crore per year.</p>

		Terms: Consideration for each of the transactions shall be determined mutually between the parties, depending on the process and product involved and shall be at an arm's length basis considering prevalent market conditions.
5	The manner of determining the pricing and other commercial terms, both included as part of contract and not considered as part of contract	The pricing/ commercial terms will be determined based on the transactions with unrelated parties for similar nature of transaction, if any. The prices/commercial terms will be determined on arm's length basis.
6	Any other information relevant or important for the members to take a decision on the proposed transaction	Mr. Jasjot Singh and Mrs. Parmjeet Kaur, being common Promoter of M/s Khanna Solvex and Ajooni Biotech Limited.

Relevant information pursuant to the Master circular for compliance with the provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 dated November 11, 2024 read with SEBI Circular dated February 14, 2025, are detailed below

A (1) Basic Details of the Related Party

S.No.	Particulars of the information	Information provided by the management
1	Name of the related party	M/s Khanna Solvex (Partnership Firm)
2	Country of incorporation of the related party	India
3	Nature of business of the related party	Trading and selling of wide range of Cattle feed and Supplements

A (2) Relationship and ownership of the related party

S.No.	Particulars of the information	Information provided by the management
4	Relationship between the listed entity/subsidiary (in case of transaction involving the subsidiary) and the related party.	Entities over which Promoters/KMP along with close member of promoter /KMP exercise significant influence.
5	Shareholding or contribution % or profit & loss sharing % of the listed entity/ subsidiary (in case of transaction involving the subsidiary), whether direct or indirect, in the related party. Explanation: Indirect shareholding shall mean shareholding held through any person, over which the listed entity or subsidiary has control.	Indirect Holding – 100%
6	Shareholding of the related party, whether direct or indirect, in the listed entity/subsidiary (in case of transaction involving the subsidiary). Explanation: Indirect shareholding shall mean shareholding held through any person, over which	Indirect Holding –26.89%

	the related party has control. While calculating indirect shareholding, shareholding held by relatives shall also be considered.	
--	--	--

A (3) Financial performance of the related party

S.No.	Particulars of the information	Information provided by the management
7	Standalone turnover of the related party for each of the last three financial years	FY 2023-2024 – Rs. 404.30 lakhs FY 2022-2023 – Rs. 359.86 lakhs FY 2021-2022 – Rs. 18.88 lakhs
8	Standalone net worth of the related party for each of the last three financial years	FY 2023-2024 – Rs. 45.03 lakhs FY 2022-2023 – Rs. 41.16 lakhs FY 2021-2022 – Rs. 38.49 lakhs
9	Standalone net profits of the related party for each of the last three financial years	FY 2023-2024 – Rs. 4.03 lakhs FY 2022-2023 – Rs. 2.67 lakhs FY 2021-2022 – Rs. 2.64 lakhs

A (4) Details of previous transactions with the related party

S.No.	Particulars of the information	Information provided by the management
10	Total amount of all the transactions undertaken by the listed entity or subsidiary with the related party during each of the last three financial years. Note: Details need to be disclosed separately for listed entity and its subsidiary.	FY 2024-25 Purchases – Rs. 1619200 Rent Paid - Rs. 518400 Advances given- Rs. 20714000 FY 2023-24 Purchases – Rs. 7168590 Rent Paid - Rs. 518400 FY 2022-23 Purchases – Rs. 7984392 Rent Paid - Rs. 518400 Sales- Rs. 10176855 Advance Given – Rs. 14600000
11	Total amount of all the transactions undertaken by the listed entity or subsidiary with the related party during the current financial year (till the date of approval of the Audit Committee / shareholders).	Rs. 3.33 crore
12	Whether prior approval of Audit Committee has been taken for the above mentioned transactions?	Yes
13	Any default, if any, made by a related party concerning any obligation undertaken by it under a transaction or arrangement entered into with the	No default made.

	listed entity or its subsidiary during the last three financial years.	
--	--	--

A (5) Amount of the proposed transactions (All types of transactions taken together)

S.No.	Particulars of the information	Information provided by the management
14	Total amount of all the proposed transactions being placed for approval in the current meeting	Max value upto Rs. 5.50 crores per annum
15	Whether the proposed transactions taken together with the transactions undertaken with the related party during the current financial year is material RPT in terms of Para 1(1) of these Standards?	No
16	Value of the proposed transactions as a percentage of the listed entity's annual consolidated turnover for the immediately preceding financial year	4.71%
17	Value of the proposed transactions as a percentage of subsidiary's annual standalone turnover for the immediately preceding financial year (in case of a transaction involving the subsidiary, and where the listed entity is not a party to the transaction)	Not applicable
18	Value of the proposed transactions as a percentage of the related party's annual standalone turnover for the immediately preceding financial year.	831%

B (1) Basic details of the proposed transaction

(In case of multiple types of proposed transactions, details to be provided separately for each type of the proposed transaction – for example, (i) sale of goods and purchase of goods to be treated as separate transactions; (ii) sale of goods and sale of services to be treated as separate transactions; (iii) giving of loans and giving of guarantee to be treated as separate transactions)

S.No.	Particulars of the information	Information provided by the management
1	Specific type of the proposed transaction (e.g. sale of goods/services, purchase of goods/services, giving loan, borrowing etc.)	Purchase or supply of goods or materials, selling or otherwise disposing of, or buying, property of any kind, leasing of property of any kind, availing or rendering of any services, reimbursement of expenses, appointment of agent for purchase or sale of goods or any, taking/giving inter-corporate loans/advances, selling/ disposing/ buying/ leasing property of any kind, payment of dividend on investment in securities, materials services or property or

		appointment of such parties to any office or place of profit in the company
2	Details of the proposed transaction	<p>Terms and conditions for transaction in ordinary course of business and at arm's length.</p> <p>1.Nature of Transaction – sale/purchase/rent paid/other transaction</p> <p>2.Delivery of Materials – As per Purchase order</p> <p>3.Payment terms – As per Agreement</p> <p>4.Indirect Taxes as applicable</p> <p>5.Currency – INR</p> <p>6.Such other conditions customary to the context of the contract/agreement/arrangement.</p>
3	Tenure of the proposed transaction (tenure in number of years or months to be specified)	15 months (with reference to SEBI circular no. SEBI/ HO/CFD/CMD1/CIR/P/2022/47)
4	Indicative date / timeline for undertaking the transaction	Approval has been sought on omnibus basis for 15 months
5	Whether omnibus approval is being sought?	Yes
6	<p>Value of the proposed transaction during a financial year. In case approval of the Audit Committee is sought for multi-year contracts, also provide the aggregate value of transactions during the tenure of the contract.</p> <p>If omnibus approval is being sought, the maximum value of a single transaction during a financial year.</p>	<p>Maximum Value: upto Rs. 5.50 crores per annum</p> <p>The maximum value of a single transaction is proposed to be Rs. 50 lakhs</p>
7	<p>Whether the RPTs proposed to be entered into are:</p> <p>(i) not prejudicial to the interest of public shareholders, and</p> <p>(ii) going to be carried out on the same terms and conditions as would be applicable to any party who is not a related party</p>	RPTs are not prejudicial to the interest of public shareholders and would be carried out on the same terms and conditions as would be applicable to any party who is not a related party.
8	Provide a clear justification for entering into the RPT, demonstrating how the proposed RPT serves the best interests of the listed entity and its public shareholders.	The proposed RPT is a strategic step that secures cost efficiency, operational stability and growth opportunities for the company. by being at arm's length and fully transparent, it protects the interest of shareholders while enabling the company to achieve its objectives sustainability.

9	<p>Details of the promoter(s)/ director(s) / key managerial personnel of the listed entity who have interest in the transaction, whether directly or indirectly.</p> <p>The details shall be provided, where the shareholding or contribution or % sharing ratio of the promoter(s) or director(s) or KMP in the related party is more than 2%.</p> <p>Explanation: Indirect interest shall mean interest held through any person over which an individual has control including interest held through relatives.</p> <p>a. Name of the director / KMP b. Shareholding of the director / KMP, whether direct or indirect, in the related party</p>	<p>Promoter and Director/ KMP- Jasjot Singh, Promoters- Upneet Kaur, Ishneet Kaur, Parmjeet Kaur and Ashmeet Kaur and Healthy Biosciences Limited</p> <p>have interest in this transaction directly or indirectly.</p> <p>Promoter / Director/ KMP having more than 2% shareholding- Parmjeet Kaur – Jasjot Singh -</p>
10	<p>Details of shareholding (more than 2%) of the director(s) / key managerial personnel/ partner(s) of the related party, directly or indirectly, in the listed entity.</p> <p>Explanation: Indirect shareholding shall mean shareholding held through any person over which an individual has control including shareholding held through relatives.</p> <p>a. Name of the director / KMP/ partner b. Shareholding of the director / KMP/ partner, whether direct or indirect, in the listed entity</p>	<p>Direct Holding Jasjot Singh -11.01% Parmjeet Kaur – 3.3%</p> <p>Indirect Holding- Healthy Biosciences Limited – 7.03% Upneet Kaur – 2.54%</p>
11	A copy of the valuation or other external party report, if any, shall be placed before the Audit Committee	Not applicable
12	Other information relevant for decision making.	-

B (2) Additional details for proposed transactions relating to sale, purchase or supply of goods or services or any other similar business transaction

S.No.	Particulars of the information	Information provided by the management
13	Number of bidders / suppliers / vendors / traders / distributors / service providers from whom bids / quotations were received with respect to the proposed transaction along with details of	No bids or quotations were obtained by Ajooni for this transaction, as it pertains to sales and purchase activities, not procurement. However, these transactions

	process followed to obtain bids.	are strategic, commercial prudent and fully aligned with market trends. All the transactions are reviewed by Audit Committee ensuring independence and fairness. Dealing with related party ensures uninterrupted supply of critical inputs, reducing the risks of volatile external markets.
14	Best bid / quotation received. If comparable bids are available, disclose the price and terms offered.	Not applicable
15	Additional cost / potential loss to the listed entity or the subsidiary in transacting with the related party compared to the best bid / quotation received.	Not applicable
16	Where bids were not invited, the fact shall be disclosed along with the justification for the same.	Not applicable
17	Wherever comparable bids are not available, state what is basis to recommend to the Audit Committee that the terms of proposed RPT are beneficial to the shareholders.	Refer point 13 and point 8 above

The contracts, agreements, arrangements and transactions so carried out shall be at arm's length basis and in Company's ordinary course of business. No advances have been paid for the said transactions as of now. However, if required in future, the advances will be paid as per industry norms, customs and usages. Further all the factors of the contract have been considered.

Pursuant to Regulation 23 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, all entities falling under the definition "Related Party" shall not vote to approve the resolution proposed at item no. 3 to 7 of the notice, irrespective of whether the entity is a party to the particular transaction or not. Accordingly, the promoters and promoter group will not vote to approve the proposed resolutions.

Mr. Jasjot Singh, Mrs. Ishneet Kaur, Ms. Upneet Kaur, Mrs. Parmjeet Kaur , Ms. Ashmeet Kaur and Healthy Biosciences Limited holds Equity shares of the company and being promoters are concerned or interested in the Ordinary resolutions to this notice.

Except the above, none of the Directors and Key Managerial persons of the Company and their relatives are concerned or interested, financial or otherwise, in the resolution set out at Item No 3 to 7 .

The Board has recommended Ordinary Resolutions at Item No. 3 to 7 for approval by the Members.

ITEM No. 8**TO CONSIDER APPOINTMENT OF M/S. SDK & ASSOCIATES, PRACTICING COMPANY SECRETARIES AS THE SECRETARIAL AUDITORS OF THE COMPANY FOR FIVE FINANCIAL YEARS FROM FY 2025-26 TO FY 2029-30.**

In terms of provisions of Regulation 24A(1)(b) of SEBI Listing Regulations read with Circular No.: SEBI/HO/CFD/CFD-PoD-2/ CIR/P/2024/185 dated 31 December 2024, a listed entity shall appoint Secretarial Auditor for a term of five consecutive years with the approval of shareholders in its AGM.

Accordingly, as per the stated regulations and as per the recommendations of the Audit Committee and the Board of Directors at the meetings held on Friday, August 29, 2025, M/s. SDK & Associates, Peer Reviewed Practicing Company Secretaries (PRC Number-7065/2025), in Chandigarh is proposed to be appointed as Secretarial Auditors of the Company, for a term of 5 consecutive years i.e. from the conclusion of the 15th Annual General Meeting, till the conclusion of 20th Annual General Meeting of the Company to conduct Secretarial Audit and issue the Secretarial Audit Reports of the Company for the said period.

M/s. SDK & Associates, have consented to the said appointment and confirmed that their appointment, if made, would be within the limits specified in Circular No.: SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated 31 December 2024. They have further confirmed that they are not disqualified to be appointed as Secretarial Auditors in terms of Disqualifications mentioned in Circular No.: SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated 31 December 2024.

The details required to be disclosed as per the provisions of Regulation 36(5) of the SEBI Listing Regulations, 2015 are as under:

S.No.	Particulars	Details
1	Proposed Secretarial Auditors	M/s. SDK & Associates
2	Basis of Recommendation for appointment	<p>Founded in 2021, SDK & Associates is a Practicing Company Secretaries firm rendering specialized services in the area of Corporate Laws, IPR's, Corporate Governance Issues, Legal drafting of agreements, Corporate Restructuring etc. and registered as a Practicing Company Secretaries Firm with Institute of Company Secretaries of India.</p> <p>SDK & Associates has immense experience and specialize in dealing with matters relating to Company Laws, Securities Law, Corporate Governance matters, Legal Due Diligence, Joint Ventures, Foreign Collaborations, Technology Transfers, Mergers and Acquisitions, Due Diligence, Listings and Capital Market Transactions.</p>
3	Details relating to Credentials of Secretarial Auditor	<p>SDK & Associates is a proprietary firm, under the stewardship of Mr. Shubham, who holds a professional degree of Company Secretary from Institute of Companies Secretaries of India, Masters of Commerce, duly registered as an Associate Member from the Institute of Company Secretaries of India.</p> <p>Shubham's experience spans around 7 years in the corporate legal field. He has worked in organizations with business interests as diverse as non-Banking, banking and manufacturing.</p>

4	Terms of Appointment	FY 2025-2026 to FY 2029-2030
---	----------------------	------------------------------

No order has been passed by ICSI/SEBI/MCA/ any other competent authority/ Court, both in India or outside India, in past 5 years against the proposed secretarial auditors.

Accordingly, the Board of Directors seeks consent of the Members by passing an Ordinary Resolution set out at Item No. 8 of the notice to consider the appointment of M/s. SDK & Associates, Practicing Company Secretaries, for the office of the Secretarial Auditor of the Company for a period of Five (5) years, from the financial year 2025-2026 to 2029-2030.

None of the Directors, Key Managerial Personnel of the Company and their relatives, are concerned or interested, financially or otherwise, in this resolution.

ITEM NO. 9

TO KEEP REGISTERS AND RETURNS AT THE CORPORATE OFFICE OF THE COMPANY

In the interest of operational and administrative convenience, Company proposes to keep and maintain the Statutory Register, records and copies of Annual Returns at the Corporate office of the Company situated at House Number 1769, Phase 3B2, S.A.S. Nagar, Mohali-160059, Punjab. Whereas, the provisions of Section 94 of the Companies Act, 2013, requires the consent and approval of the members of the Company to keep the Statutory Register, records and copies of Annual Returns at the Corporate Office of the Company at a place other than its registered office.

The Board recommends passing of Resolution as set out as Item Number 9 of this notice as a Special Resolution by the shareholders.

None of the promoters, Directors and Key Managerial Personnel of the Company and their relative are in any way interested in the special resolution set out under Item No. 9 of the Notice.

ITEM NO. 10

TO APPROVE REMUNERATION OF MR. GURMEET SINGH FOR HOLDING AN OFFICE OR PLACE OF PROFIT IN THE COMPANY

The Companies Act, 2013 aims to ensure transparency and dealing with related parties of the Company. The provisions of section 188(1)(f) of the Companies Act, 2013 and Rule 15(1)(f) of the Companies (Meetings of Board and its Powers) Rules, 2014, and read with Regulation 23 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 governs the related party's appointment to any office or place of profit in the Company, its subsidiary company or associate company. Mr. Gurmeet Singh, father of Mr. Jasjot Singh (Director of the Company) was appointed as General Manager, holding an office of place or profit under section

188 and all other applicable provisions of the Companies, Act, 2013 read with the Rules made thereunder at monthly gross salary not exceeding Rs. 5,00,000 per month along with other perquisites. Mr. Gurmeet Singh is associated with Company from last few years and meanwhile gave his best for Company's immense growth. Considering his qualification, experience and present role current compensation is not as per standards, hence requires approval of the Shareholders.

The Board believes that the continued engagement of Mr. Gurmeet Singh, is beneficial for the Company, given his qualifications and experience.

Further, pursuant to the SEBI Circular No. SEBI/HO/CFD/CFDPoD- 2/P/CIR/2025/18 dated February 14, 2025, the listed companies are required to place minimum information for review of the audit committee and shareholders for approval of RPTs as per the Industrial Standards issued by Industry Standards Forum (ISF). Relevant information pursuant to the Master circular for compliance with the provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 dated November 11, 2024 read with SEBI Circular dated February 14, 2025, are as follows:

A (1) Basic Details of the Related Party

S.No.	Particulars of the information	Information provided by the management
1	Name of the related party	Mr. Gurmeet Singh
2	Country of incorporation of the related party	Not applicable
3	Nature of business of the related party	Employee

A (2) Relationship and ownership of the related party

S.No.	Particulars of the information	Information provided by the management
4	Relationship between the listed entity/subsidiary (in case of transaction involving the subsidiary) and the related party.	Office or place of profit
5	Shareholding or contribution % or profit & loss sharing % of the listed entity/ subsidiary (in case of transaction involving the subsidiary), whether direct or indirect, in the related party. Explanation: Indirect shareholding shall mean shareholding held through any person, over which the listed entity or subsidiary has control.	Nil
6	Shareholding of the related party, whether direct or indirect, in the listed entity/subsidiary (in case of transaction involving the subsidiary). Explanation: Indirect shareholding shall mean shareholding held through any person, over which the related party has control. While calculating	Nil

	indirect shareholding, shareholding held by relatives shall also be considered.	
--	---	--

A (3) Financial performance of the related party - NIL

A (4) Details of previous transactions with the related party

S.No.	Particulars of the information	Information provided by the management
10	Total amount of all the transactions undertaken by the listed entity or subsidiary with the related party during each of the last three financial years. Note: Details need to be disclosed separately for listed entity and its subsidiary.	FY 2024-25 Remuneration paid- Rs. 30 lakhs p.a. FY 2023-24 Remuneration paid- Rs. 14.50 lakhs p.a. FY 2022-23 Remuneration paid- Rs. 12 lakhs pa.a.
11	Total amount of all the transactions undertaken by the listed entity or subsidiary with the related party during the current financial year (till the date of approval of the Audit Committee / shareholders).	Rs. 12 lakhs (till 30 th June 2025)
12	Whether prior approval of Audit Committee has been taken for the above mentioned transactions?	Yes
13	Any default, if any, made by a related party concerning any obligation undertaken by it under a transaction or arrangement entered into with the listed entity or its subsidiary during the last three financial years.	No default made.

A (5) Amount of the proposed transactions (All types of transactions taken together)

S.No.	Particulars of the information	Information provided by the management
14	Total amount of all the proposed transactions being placed for approval in the current meeting	Max value upto Rs. 60 lakhs Per annum
15	Whether the proposed transactions taken together with the transactions undertaken with the related party during the current financial year is material RPT in terms of Para 1(1) of these Standards?	Yes
16	Value of the proposed transactions as a percentage of the listed entity's annual consolidated turnover for the immediately preceding financial year	0.51%

17	Value of the proposed transactions as a percentage of subsidiary's annual standalone turnover for the immediately preceding financial year (in case of a transaction involving the subsidiary, and where the listed entity is not a party to the transaction)	Not applicable
18	Value of the proposed transactions as a percentage of the related party's annual standalone turnover for the immediately preceding financial year.	Not applicable

B (1) Basic details of the proposed transaction

(In case of multiple types of proposed transactions, details to be provided separately for each type of the proposed transaction – for example, (i) sale of goods and purchase of goods to be treated as separate transactions; (ii) sale of goods and sale of services to be treated as separate transactions; (iii) giving of loans and giving of guarantee to be treated as separate transactions)

S.No.	Particulars of the information	Information provided by the management
1	Specific type of the proposed transaction (e.g. sale of goods/services, purchase of goods/services, giving loan, borrowing etc.)	Remuneration to Mr. Gurmeet Singh, father of Mr. Jasjot Singh.
2	Details of the proposed transaction	Terms and conditions for transaction in ordinary course of business and at arm's length. 1. Mr. Gurmeet Singh is employed as General Manager in Ajooni Biotech Limited 2. Terms and conditions for employment are as per Company Policy 3. Nature of Transaction – Remuneration (Office or place of profit)
3	Tenure of the proposed transaction (tenure in number of years or months to be specified)	As per the terms of employment
4	Indicative date / timeline for undertaking the transaction	With effect from April 01, 2025
5	Whether omnibus approval is being sought?	Yes
6	Value of the proposed transaction during a financial year. In case approval of the Audit Committee is sought for multi-year contracts, also provide the aggregate value of transactions during the tenure of the contract. If omnibus approval is being sought, the maximum value of a single transaction during a	Maximum Value: upto Rs. 60 lakhs Per annum The maximum value of a single transaction is proposed to be Rs. 10 lakhs

	financial year.	
7	<p>Whether the RPTs proposed to be entered into are:</p> <p>(i) not prejudicial to the interest of public shareholders, and</p> <p>(ii) going to be carried out on the same terms and conditions as would be applicable to any party who is not a related party</p>	RPTs are not prejudicial to the interest of public shareholders and would be carried out on the same terms and conditions as would be applicable to any party who is not a related party.
8	Provide a clear justification for entering into the RPT, demonstrating how the proposed RPT serves the best interests of the listed entity and its public shareholders.	His leadership has been pivotal in expanding business operations across diverse territories and regions, driving revenue growth and market penetration. Mr. Bhatia's adeptness in developing and executing business plans aligned with organizational objectives has been instrumental in navigating complex landscapes and capitalizing on emerging technologies. With expertise spanning sectors like Security Printing, Renewable Energy, Agri-Biotechnology, Vet-Pharma, and animal healthcare, he has effectively utilize his skills in finance, marketing, human relations, and operations to deliver results consistently. Mr. Bhatia believes that passion, patience, persistence, and perseverance form an unbeatable combination for success.
9	<p>Details of the promoter(s)/ director(s) / key managerial personnel of the listed entity who have interest in the transaction, whether directly or indirectly.</p> <p>The details shall be provided, where the shareholding or contribution or % sharing ratio of the promoter(s) or director(s) or KMP in the related party is more than 2%.</p> <p>Explanation: Indirect interest shall mean interest held through any person over which an individual has control including interest held through relatives.</p> <p>a. Name of the director / KMP</p> <p>b. Shareholding of the director / KMP, whether direct or indirect, in the related party</p>	<p>Promoter and Director/ KMP- Jasjot Singh,</p> <p>Promoters- Upneet Kaur, Ishneet Kaur, Parmjeet Kaur and Ashmeet Kaur and Healthy Biosciences Limited</p> <p>have interest in this transaction directly or indirectly.</p>
10	Details of shareholding (more than 2%) of the director(s) / key managerial personnel/ partner(s) of the related party, directly or indirectly, in the	Not applicable

	<p>listed entity. Explanation: Indirect shareholding shall mean shareholding held through any person over which an individual has control including shareholding held through relatives.</p> <p>a. Name of the director / KMP/ partner b. Shareholding of the director / KMP/ partner, whether direct or indirect, in the listed entity</p>	
11	A copy of the valuation or other external party report, if any, shall be placed before the Audit Committee	Not applicable
12	Other information relevant for decision making.	-

The Board, based on the recommendation of the Audit Committee, recommends the approval of the Members by passing of the Ordinary Resolution set out at Item No. 10 of this Notice.

Mr. Jasjot Singh, Mrs. Ishneet Kaur, Ms. Upneet Kaur, Mrs. Parmjeet Kaur , Ms. Ashmeet Kaur and Healthy Biosciences Limited holds Equity shares of the company and being promoters are concerned or interested in the Ordinary resolutions to this notice.

Except the above, none of the Directors and Key Managerial persons of the Company and their relatives are concerned or interested, financial or otherwise, in the resolution set out at Item No 10 .

ITEM NO. 11

TO RE-APPOINT MR. GURSIMRAN SINGH (DIN: 02209675) AS A WHOLE TIME DIRECTOR OF THE COMPANY AND FIX HIS REMUNERATION

The members are informed that Mr. Gursimran Singh is 37 years old and holds degree of Master in Business Administration (MBA). He has more than 15 years of experience in the field of animal husbandry, cultivation of crops and supplements required for livestock. He is an expert and leading entrepreneur in the field of agriculture and has vide expertise as marketing professional and expert knowledge of cultivation of crops/supplements.

Pursuant to recommendation of Nomination and Remuneration Committee of the Company held on 08th August 2025, and the Board of Directors of the Company, at their meeting held on 14th August 2025, have unanimously approved the reappointment of Mr. Gursimran Singh as the Whole Time Director with effect from 14th August 2025 and remuneration payable not exceeding Rs. 2,00,000 per month subject to the approval of Shareholders at this Annual General Meeting. The Members may note that the tenure of appointment of Mr. Gursimran Singh, is period of 5 (five) years), i.e., effective from 14th August 2025 to 13th August, 2030 for which approval of the shareholders is being sought. The Members may note that the

Company has received a letter of consent from Mr. Gursimran Singh signifying his willingness to be appointed as Whole Time Director, a declaration under section 164 of the Companies Act, 2013 and other statutory disclosures/declarations as required under the law. The essential terms and condition of his appointment and remuneration are as under;

- a) Mr. Gursimran Singh shall be responsible for overseeing for the day to day operations and management of the Company and such other matters as identified by the Board from time to time. He shall devote his whole time and attention to the business of the Company. He shall exercise and perform all such powers and duties as the Board of Directors of the Company shall, from time to time, determine, and subject to the superintendence, control, direction, and restriction from time to time give and imposed by the Board and/or the Articles of Association of the Company and shall not exceed the powers so delegated by the Board.
- b) Period of Agreement: 14th August 2025 to 13th August, 2030.
- c) Minimum Remuneration: In the event of loss or inadequacy of profits in any year during the tenure of the Whole Time Director, Mr. Gursimran Singh shall be paid remuneration as above as minimum remuneration.
- d) Sitting fees: Mr. Gursimran Singh shall not be paid sitting fees for attending the Board meetings and meetings of the Committee in which he may be nominated as a member.

Mr. Gursimran Singh hold 1815 equity shares in the Company. The draft of the agreement shall be open for inspection by the Members at the Registered office of the Company during the normal business hours on any working day, excluding Sunday. Having regard to his qualifications, experience and association with the Company, the Board of Directors considers that it will be in the interest of the Company to appoint Mr. Gursimran Singh as the Whole Time Director of the Company for a term of 5 years from 14th August 2025 to 13th August, 2030 .

Further the members are informed that as per the provisions of Section 197 of the Companies Act, 2013 read with Rules made thereunder and Schedule V of the Act the company shall pay remuneration exceeding ten per cent of the net profit calculated under Section 198 of the Act in a financial year to its managing director and whole-time director and manager taken together in case it is approved by the members by way of Special Resolution.

Your Directors recommend the Resolution set out in Item No. 11 of this AGM Notice to the Members for their consideration and approval by Special Resolution.

The details of proposed remuneration and other terms and conditions are as follows:

Salary	An amount not exceeding Rs. 2,00,000/- (Rupees Two Lakhs only) per month inclusive of perquisites as detailed below
Perquisites	<ol style="list-style-type: none"> a. House maintenance allowance together with reimbursement of expenses or allowances for utilities as electricity, security, maintenance, staff salary etc. b. Reimbursement of expenses pertaining to electricity, gas, water, telephone and other reasonable expenses for the upkeep and maintenance in respect of such accommodation. c. Contribution towards Provident Fund and Superannuation Fund or Annuity Fund, National Pension Scheme - as per the policy of the Company.

	<p>d. Leave and encashment of leave - as per the policy of the Company.</p> <p>e. Gratuity and / or contribution to the Gratuity Fund of Company - as applicable to other officers of the Company and as per the policy of the Company</p> <p>f. Other Allowances / benefits, perquisites - as per the Rules applicable to the Senior Executives of the Company and / or which may become applicable in the future and or any other allowance, perquisites as the Board may from time to time decide.</p>
Other Terms and Conditions	<ul style="list-style-type: none"> • No sitting fees shall be paid for attending the meetings of the Board of Directors or Committees thereof.

Information pursuant to Regulation 36(3) of SEBI(LODR) Regulations, 2015 and Secretarial Standard 2 issued by the Institute of Company Secretaries of India is provided as **Annexure** respectively to this Notice.

Annexure

Details of the Director seeking appointment/ re-appointment as required under Regulation 36(3) of SEBI(LODR) Regulations, 2015 and Secretarial Standards issued by Institute of Company Secretaries of India:-

S.NO.	PARTICULARS	INFORMATION
1.	Type of event	Re-appointment of Mr. Gursimran Singh as Whole Time Director of the Company
2.	Date of Birth	23/02/1988
3.	Date of Appointment on the Board	13 th August 2020
4.	Tenure of Appointment	5 years
5.	DIN	02209675
6.	Nationality	Indian
7.	Category	Whole Time Director
8.	Qualification	He is qualified as Bachelor of Commerce (B.Com) and Master in Business Administration (MBA)
9.	Brief Profile/ Expertise	Mr. Gursimran Singh is having more than 15 years of experience in the field of Animal Husbandry, cultivation of crops and supplements required for livestock. He is also working as CEO of Ajooni Biotech Limited since past 8 years of the company. He is an expert and leading entrepreneur in the field of agriculture and has vide expertise as marketing professional and expert knowledge of cultivation of crops/ supplements.
10.	List of other companies in which Directorship is held as on 31.03.2025	HEALTHY BIOSCIENCES LIMITED (CIN: U24296PB2008PLC032037)
11.	Chairman/ Member of The Committee of the Board Of the	Nil

	Other Companies in which he is a director as on 31.03.2025.	
12.	Equity Shares held in the Company as on 31.03.2025	1815
13.	Disclosure of relationships between existing directors and new director	Not related to any director

Save and except the above, none of the other Directors / Key Managerial Personnel of the Company / their relatives are, in any way, concerned or interested, financially or otherwise, in the resolution set out at Item No. 11 of the Notice. The Board commends the **Special Resolution** set out at Item No. 11 of the Notice for approval by the members.

ITEM NO. 12

TO RE-APPOINT MR. JASJOT SINGH (DIN: 01937631) AS A MANAGING DIRECTOR OF THE COMPANY AND INCREASE IN REMUNERATION

Pursuant to recommendation of Nomination and Remuneration Committee of the Company held on 10th June 2025, and the Board of Directors of the Company, at their meeting held on 01st July 2025, have unanimously approved the reappointment of Mr. Jasjot Singh as the Managing Director of the company with effect from April 01, 2025 and remuneration payable not exceeding Rs. 4,00,000 per month subject to the approval of Shareholders at this Annual General Meeting

Further the members are informed that as per the provisions of Section 197 of the Companies Act, 2013 read with Rules made thereunder and Schedule V of the Act the company shall pay remuneration exceeding ten per cent of the net profit calculated under Section 198 of the Act in a financial year to its managing director and whole-time director and manager taken together in case it is approved by the members by way of Special Resolution.

Your Directors recommend the Resolution set out in Item No. 12 of this AGM Notice to the Members for their consideration and approval by Special Resolution.

None of the Promoters, Directors, Key Managerial Personnel of the Company or their relative are in anyway concerned or interested, financially or otherwise, in the Resolution except Mr. Jasjot Singh.

The details of proposed remuneration and other terms and conditions are as follows:

Salary	An amount not exceeding Rs. 400000/- (Rupees Four Lakhs only) per month inclusive of perquisites as detailed below
Perquisites	a. House maintenance allowance together with reimbursement of expenses or allowances for utilities as electricity, security, maintenance, staff salary etc. b. Reimbursement of expenses pertaining to electricity, gas, water, telephone and other reasonable expenses for the upkeep and maintenance in respect of such accommodation.

	c. Contribution towards Provident Fund and Superannuation Fund or Annuity Fund, National Pension Scheme - as per the policy of the Company. d. Leave and encashment of leave - as per the policy of the Company. e. Gratuity and / or contribution to the Gratuity Fund of Company - as applicable to other officers of the Company and as per the policy of the Company f. Other Allowances / benefits, perquisites - as per the Rules applicable to the Senior Executives of the Company and / or which may become applicable in the future and or any other allowance, perquisites as the Board may from time to time decide.
Other Terms and Conditions	<ul style="list-style-type: none"> No sitting fees shall be paid for attending the meetings of the Board of Directors or Committees thereof.

Information pursuant Regulation 36(3) of SEBI(LODR) Regulations, 2015 and Secretarial Standard 2 issued by the Institute of Company Secretaries of India is provided as **Annexure** respectively to this Notice.

Annexure

Details of the Director seeking appointment/ re-appointment as required under Regulation 36(3) of SEBI(LODR) Regulations, 2015 and Secretarial Standards issued by Institute of Company Secretaries of India:-

S.N O.	PARTICULARS	INFORMATION
1.	Type of event	Re-appointment of Mr. Jasjot Singh as the Managing Director of the Company
2.	Date of Birth	30/06/1985
3.	Date of Appointment on the Board	02 nd August 2017
4.	Tenure of Appointment	5 years
5.	DIN	01937631
6.	Nationality	Indian
7.	Category	Promoter/ Managing Director
8.	Qualification	He is qualified as Master in Business Administration (MBA) in Finance from Oxford University, U.K.
9.	Brief Profile/ Expertise	He is having more than 17 years of experience in the field of domestic, Finance, Taxation as well as in the global Business Scenario. He is a leading entrepreneur in domestic cattle feed supplements, Finance, Taxation. He has worked with Healthy Biosciences Pvt. Limited, venture with Patanjali Research Center. He has also set up a factory unit for manufacturing of cattle feed in Khanna, Punjab and served in the growth of the business.
10.	List of other companies in which Directorship is held as on 31.03.2025	Healthy Biosciences Limited Gilbert Kasauli Private Limited

11.	Chairman/ Member of The Committee of the Board Of the Other Companies in which she is a director as on 31.03.2025.	Nil
12.	Equity Shares held in the Company as on 31.03.2025	18968521
13.	Disclosure of relationships between existing directors and new director	Not related to any director.

Save and except the above, none of the other Directors / Key Managerial Personnel of the Company / their relatives are, in any way, concerned or interested, financially or otherwise, in the resolution set out at Item No. 12 of the Notice. The Board commends the Special Resolution set out at Item No. 12 of the Notice for approval by the members.

ITEM NO. 13

TO APPROVE THE ADVANCEMENT OF LOANS, GUARANTEE OR SECURITY TO ANY PERSON IN WHOM ANY OF THE DIRECTOR OF THE COMPANY IS INTERESTED UNDER SECTION 185 OF COMPANIES ACT, 2013

The Company is expected to render support for the business requirements of other companies in the group (i.e. entities in which directors of the Company are interested as per the provisions of section 185 of the Companies Act, 2013), from time to time. However, owing to certain restrictive provisions contained in the Section 185 of the Companies Act, 2013, the Company was unable to extend financial assistance by way of loan, guarantee or security to other entities in the Group.

In the light of amendments notified, inter-alia replacing the provisions Section 185 of Companies Act, 2013, the Company with the approval of members by way of special resolution, may advance any loan including any loan represented by a book debt, or give any guarantee or provide any security in connection with any loan taken by any person in whom any of the director of the Company is interested in respect of loans taken by such entities, for their principal business activities.

Accordingly, in order to meet the funding requirements and ensure necessary compliances of the provisions of the Companies Act, 2013, the Board of Directors, hereby proposes to grant loans or provide guarantee/security to these below mentioned entity upto an aggregate amount not exceeding Rs. 55 Crores (Rupees Fifty Five Crores only) during a financial year, in its absolute discretion deem beneficial and in the best interest of the Company. The details of the existing group companies/ associate companies /Subsidiaries/Joint Venture Companies in which any of the Directors of the Company is interested as specified in the explanation to section 185(2) of the Act are as follows:

S. No.	Name of Party	Nature of Relationship	Purpose
1.	Healthy Biosciences Limited	Common Directorship (Mr. Jasjot Singh and Mr. Gursimran Singh) between	Procurement of plant and machineries, sale and purchase of goods/ services, fixed assets or any other expense

		Healthy Biosciences Limited and Ajooni Biotech Limited.	including working capital requirements to support its principal business activities.
2.	Punjab Biotechnology Park Limited	Common Promoters (Mr. Gurmeet Singh, Mr. Jasjot Singh, Mr. Gursimran Singh and Mrs. Parmjeet Kaur) between Punjab Biotechnology Park Limited and Ajooni Biotech Limited.	Procurement of plant and machineries, sale and purchase of goods/ services, fixed assets or any other expense including working capital requirements to support its principal business activities.
3.	Revive Aesthetics Private Limited	Common Promoters (Ms. Upneet Kaur) between Revive Aesthetics Private Limited and Ajooni Biotech Limited.	Procurement of plant and machineries, sale and purchase of goods/ services, fixed assets or any other expense including working capital requirements to support its principal business activities.
4.	Gilbert Kasauli Private Limited	Common Director (Mr. Jasjot Singh) Between Gilbert Kasauli Private Limited and Ajooni Biotech Limited	Procurement of plant and machineries, sale and purchase of goods/ services, fixed assets or any other expense including working capital requirements to support its principal business activities.
5.	M/s Khanna Solvex	Common Director/Partner (Mr. Jasjot Singh) and Common Promoter (Mrs. Parmjeet Kaur) between Khanna Solvex and Ajooni Biotech Limited.	Procurement of plant and machineries, sale and purchase of goods/ services, fixed assets or any other expense including working capital requirements to support its principal business activities.

Further, other relevant facts related to the loan, guarantee or security to any person in whom any of the director of the Company is interested under section 185 of companies act, 2013 proposed to be given is as under:

Loan Amount	Up to maximum amount of Rs. 55 Crores (Rupees Fifty Five Crores only) in one or more tranches by way of a loan, guarantee or security.
Interest rate	As may be specified by the Board/Committee at the time of grant, subject to the condition that an annualized rate of interest on loan shall not be less than the prevailing yield rate applicable to the period of 1 (one) year, 3 (three) year, 5 (five) year or 10 (ten) year Government Security that is closest to the tenor of the loan.

Schedule of repayment of principal and interest	Repayable either on demand or such further period as may be extended by the Board/committee from time to time.
Interest payment schedule	As may be specified by the Board/Committee at the time of grant.
Purpose of loan	For principle business activities only.

The Board recommends the Special Resolution set out at item no. 13 of the Notice for approval by the Members.

None of the Directors, promoters and Key Managerial Personnel of the Company and their relatives is in any way concerned or interested, financially or otherwise in the resolution except to the extent of their directorship and shareholding in the body corporate(s) in which investment may be made or loan/ guarantees may be given pursuant to this Special Resolution.

ITEM NO. 14

TO APPROVE INVESTMENT/ GIVING ANY LOAN OR GUARANTEE/ PROVIDING SECURITY UNDER SECTION 186 OF COMPANIES ACT, 2013

In order to make optimum use of funds available with the Company and also to achieve long term strategic and business objectives, the Board of Directors of the Company proposes to make use of the same by making investment in other bodies corporate or granting loans, giving guarantee or providing security to other persons or other body corporate or as and when required. In accordance with the provisions Section 186 of the Companies Act, 2013 (the 'Act'), it would be necessary to obtain the approval of the members for:-

- making loans to any person or other bodies corporate;
- giving guarantee or provide security in connection with a loan to any other bodies corporate or person; and
- acquiring by way of subscription, purchase or otherwise, the securities of any other body corporate, in excess of the limits of:-
 - 60% of the paid-up share capital and free reserves and securities premium account; or
 - 100% of the free reserves and securities premium account; whichever is higher.

Considering the long term business plans of the Company, which requires the Company to make sizeable loans / investments and issue guarantees / securities to persons or bodies corporate, from time to time, prior approval of the Members is being sought for enhancing the limit up to an aggregate sum of Rs. 55 Crores (Rupees Fifty Five Crores Only). No loan shall be given under this section at a rate of interest lower than the prevailing yield of one year, three year, five year or ten year Government Security closest to the tenor of the loan.

The Board recommends passing of Resolution as set out as Item Number 14 of this notice as a Special Resolution.

None of the Directors, promoters and Key Managerial Personnel of the Company and their relatives is in any way concerned or interested, financially or otherwise in the resolution except to the extent of their directorship and shareholding in the body corporate(s) in which investment may be made or loan/ guarantees may be given pursuant to this special resolution.

Date: 29/08/2025

Place: Mohali

**By Order of the Board of Directors
For Ajooni Biotech Limited**

**Sd/-
Swati Vijan
F13627
Company Secretary**

NOTES:

1. An Explanatory Statement pursuant to Section 102 of the Companies Act, 2013 and Rules framed thereunder, in respect of the Special Business under Item Nos. 3 to 14 of the accompanying Notice are annexed hereto.
2. In accordance with the provisions of the Act, read with the Rules made thereunder and General Circular nos. 14/2020 dated April 08, 2020, 17/2020 dated April 13, 2020, 20/2020 dated May 05, 2020, 02/2021 dated January 13, 2021, 21/2021 dated December 14, 2021, 2/2022 dated May 05, 2022, 10/2022 dated December 28, 2022 and 09/2023 dated September 25, 2023 and Circular no. 9/2024 dated September 19, 2024 issued by the Ministry of Corporate Affairs ("MCA") read with relevant circulars issued by the Securities and Exchange Board of India ("SEBI"), from time to time (hereinafter collectively referred to as "the Circulars"), companies are allowed to hold AGM through Video Conference ("VC") or Other Audio Visual Means ("OAVM") upto September 30, 2025 without the physical presence of members at a common venue. Hence, in compliance with the Circulars, the AGM of the Company is being held through VC/OAVM.
3. Pursuant to the Circular No. 14/2020 dated April 08, 2020, and MCA General Circular No. 10/2022 dated 28th December, 2022 issued by the Ministry of Corporate Affairs, read with Securities and Exchange Board of India Circular No. SEBI/HO/CFD/CMD2/CIR/P/2022/62 dated 13th May 2022 and SEBI/HO/CFD/PoD-2/P/CIR/2023/4 dated 5th January, 2023, the facility to appoint proxy to attend and cast vote for the Members is not available for this AGM. However, the Body Corporates are entitled to appoint authorised representatives to attend the AGM through VC and participate thereat and cast their votes through e-Voting.
4. In compliance with MCA Circular No. 20/2020 dated May 5, 2020 and SEBI Circular No. SEBI/HO/CFD/CMD1/CIR/P/2020/79 dated May 12, 2020 and SEBI Circular No. SEBI/HO/CFD/CMD2/CIR/ P/2021/11 dated January 15, 2021, owing to the difficulties involved in dispatching of physical copies of the financial statements including Board's Report, Auditor's report or other documents required to be attached therewith (together referred to as Annual Report FY24) and Notice of AGM are being sent in electronic mode to Members whose e-mail address is registered with the Company or the Depository Participant(s) as on August 16, 2024 and to all other persons so entitled. The Notice can also be accessed from the websites of the Stock Exchange i.e. National Stock Exchange of India Limited at www.nseindia.com respectively and the AGM Notice is also available on the website of NSDL (agency for providing the Remote e-Voting facility) i.e. www.evoting.nsdl.com.
5. The Members can join the AGM in the VC mode 15 minutes before and after the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice. The facility of participation at the AGM through VC will be made available for 1,000 Members on first come first served basis. However, this number does not include the large Shareholders i.e. Shareholders holding 2% or more shareholding, Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairman of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors etc. who are allowed to attend the AGM without restriction on account of first come first served basis.
6. National Securities Depositories Limited ("NSDL") will be providing facility for voting through remote e-Voting, for participation in the AGM through VC/OAVM Facility and e-Voting during the AGM.

7. Attendance of the Members participating in the AGM through VC/OAVM Facility shall be counted for the purpose of reckoning the quorum under Section 103 of the Act.
8. Pursuant to the provisions of Section 108 of the Act read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended), Secretarial Standard on General Meetings (SS-2) issued by the Institute of Company Secretaries of India ("ICSI") and Regulation 44 of Listing Regulations read with MCA Circulars and SEBI Circular, the Company is providing remote e-Voting facility to its Members in respect of the business to be transacted at the AGM and facility for those Members participating in the AGM to cast vote through e-Voting system during the AGM.
9. Pursuant to Section 91 of the Companies Act, 2013 and Rule 10 of the Companies (Management and Administration) Rules, 2014 read with Regulation 42(5) of the Listing Regulations, the Share Transfer Books and Register of Members of the Company will remain closed from Tuesday, September 23, 2025 to Monday, September 29, 2025 (both days inclusive).
10. A member may participate in the meeting even after exercising his right to vote through remote e-voting but shall not be allowed to vote again at the meeting.
11. A person, whose name is recorded in the register of members or in the register of beneficial owners maintained by the depositories as on cut-off date only shall be entitled to avail the facility of remote e-voting.
12. Mr. Mast Ram, prop. of M/s. M.R. Chechi & Associates, Practicing Company Secretaries, Chandigarh has been appointed as the Scrutinizer to scrutinize the e-voting process in a fair and transparent manner.
13. The Scrutinizer shall, immediately after the conclusion of e-voting at Annual General Meeting, download the votes cast at the AGM and thereafter unblock the votes cast through remote e-voting in the presence of at least two witnesses not in the employment of the Company. Scrutinizer shall within 48 hours of conclusion of the meeting submit a consolidated scrutinizer report of the total votes cast in favor or against, if any, to the Chairman or a person authorized by him in writing.
14. The results along with the Scrutinizers Report shall be placed on the website of the Company and on the website of NSDL and also be immediately forwarded to Stock Exchange.
15. The Register of Directors and Key Managerial Personnel and their shareholding, maintained under Section 170 of the Companies Act, 2013 will be available for inspection by the members at the Annual General Meeting of the Company.
16. The Register of Contracts or Arrangements in which the Directors are interested, maintained under Section 189 of the Companies Act, 2013 will be available for inspection by the Members at the Annual General Meeting of the Company.
17. The Ministry of Corporate Affairs (MCA), Government of India has introduced 'Green Initiative in Corporate Governance' by allowing paperless compliance by the Companies for service of documents to their Members through electronic mode, which will be in compliance with Section 20 of the Companies Act, 2013 and Rules framed there under.

18. The transfer of Unclaimed Dividend to Investor Education & Protection Fund of the Central Government as required in terms of Section 124 of the Companies Act, 2013, during the current Financial Year is not applicable.
19. The deemed venue for AGM shall be the Registered Office of the Company.
20. Since the AGM will be held through VC/OAVM Facility, the Route Map is not annexed in this Notice.
21. Information as required under Regulation 36(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') and the Secretarial Standard on General Meetings (SS-2) issued by the Institute of Company Secretaries of India (ICSI), in respect of the Directors seeking appointment / re-appointment at the AGM is provided under a separate heading, which forms part of this Notice is annexed hereto.
22. The Securities and Exchange Board of India (SEBI) has mandated the submission of Permanent Account Number (PAN) by every participant in securities market. Members holding shares in electronic form are, therefore, requested to submit the PAN to their depository participants with whom they are maintaining their demat accounts. Members holding shares in physical form are requested to submit their PAN details to the Company.
23. Pursuant to Section 108 of the Companies Act, 2013, read with the relevant Rules of the Act, the Company is pleased to provide the facility to Members to exercise their right to vote by electronic means. The Members desiring to vote through electronic mode may refer to the detailed procedure on e-voting given hereinafter.

THE INSTRUCTIONS FOR MEMBERS FOR REMOTE E-VOTING AND JOINING GENERALMEETING ARE AS UNDER: -

The remote e-Voting period begins on Friday, September 26, 2025 at 09:00 A.M. and ends on Sunday, September 28, 2025 at 5:00 P.M. The remote e-Voting module shall be disabled by NSDL for voting thereafter. The Members, whose names appear in the Register of Members/ Beneficial Owners as on the record date (cut-off date) i.e. September 12, 2025 may cast their vote electronically. The voting right of Shareholders shall be in proportion to their share in the paid-up equity share capital of the Company as on the cut-off date, being September 12, 2025.

How do I vote electronically using NSDL e-Voting system?


The way to vote electronically on NSDL e-Voting system consists of "Two Steps" which are mentioned below:

Step 1: Access to NSDL e-Voting system

A) Login method for e-Voting and joining virtual meeting for Individual Shareholders holding securities in demat mode

In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual Shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email ID in their demat accounts in order to access e-Voting facility.

Login method for Individual Shareholders holding securities in demat mode is given below:

Type of Shareholders	Login Method
Individual Shareholders holding securities in demat mode with NSDL.	<p>If you are already registered for NSDL IDeAS facility, please visit the e-Services website of NSDL. Open web browser by typing the following URL: https://eservices.nsdl.com/ either on a Personal Computer or on a mobile. Once the home page of e-Services is launched, click on the “Beneficial Owner” icon under “Login” which is available under “IDeAS” section. A new screen will open. You will have to enter your User ID and Password. After successful authentication, you will be able to see e-Voting services. Click on “Access to e-Voting” under e-Voting services and you will be able to see e-Voting page. Click on options available against Company name or e-Voting service provider-NSDL and you will be re-directed to NSDL e-Voting website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.</p> <p>If the user is not registered for IDeAS e-Services, option to register is available at https://eservices.nsdl.com. Select “Register Online for IDeAS” Portal or click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp</p> <p>Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon “Login” which is available under ‘Shareholder/ Member’ section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number held with NSDL), Password/ OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on options available against Company name or e-Voting service provider-NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.</p> <p>Shareholders/Members can also download NSDL Mobile App “NSDL Speede” facility by scanning the QR code mentioned below for seamless voting experience.</p> <div data-bbox="613 1528 911 1671">  </div>
Individual Shareholders holding securities in demat mode with CDSL	<p>Existing users who have opted for Easi/ Easiest, they can login through their user id and password. Option will be made available to reach e-Voting page without any further authentication. The URL for users to login to Easi/ Easiest are https://web.cdslindia.com/myeasi/home/login or www.cdslindia.com and click on New System Myeasi.</p> <p>After successful login of Easi/ Easiest the user will be also able to see the E</p>

	<p>Voting Menu. The Menu will have links of e-Voting service provider i.e. NSDL. Click on NSDL to cast your vote.</p> <p>If the user is not registered for Easi/ Easiest, option to register is available at https://web.cdslindia.com/myeasi/Registration/EasiRegistration.</p> <p>Alternatively, the user can directly access e-Voting page by providing demat Account Number and PAN No. from a link in www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the demat Account. After successful authentication, user will be provided links for the respective ESP i.e. NSDL where the e-Voting is in progress.</p>
Individual Shareholders (holding securities in demat mode) login through their depository participants	<p>You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/ CDSL for e-Voting facility. Once login, you will be able to see e-Voting option. Once you click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on options available against Company name or e-Voting service provider-NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.</p>

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget UserID and Forget Password option available at above mentioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. NSDL and CDSL.

Login type	Helpdesk details
Individual Shareholders holding securities in demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.co.in or call at toll free no.: 1800 1020 990 and 1800 22 44 30
Individual Shareholders holding securities in demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at 022-23058738 or 022-23058542-43

B) Login Method for e-Voting and joining virtual meeting for Shareholders other than Individual Shareholders holding securities in demat mode and Shareholders holding securities in physical mode.

How to Log-in to NSDL e-Voting website?

1. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: <https://www.evoting.nsdl.com/> either on a Personal Computer or on a mobile.
2. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/ Member' section.
3. A new screen will open. You will have to enter your User ID, your Password/ OTP and a Verification Code as

shown on the screen.

Alternatively, if you are registered for NSDL eservices i.e. IDEAS, you can log-in at <https://eservices.nsdl.com/> with your existing IDEAS login. Once you log-in to NSDL eservices after using your log-in credentials, click on e-Voting and you can proceed to Step 2 i.e. Cast your vote electronically.

4. Your User ID details are given below:

Manner of holding shares i.e. Demat (NSDL or CDSL) or Physical	Your User ID is:
a) For Members who hold shares in demat account with NSDL.	8 Character DP ID followed by 8 Digit Client ID For example if your DP ID is IN300*** and Client ID is 12***** then your user ID is IN300***12*****.
b) For Members who hold shares in demat account with CDSL.	16 Digit Beneficiary ID For example if your Beneficiary ID is 12***** then your user ID is 12*****.
c) For Members holding shares in Physical Form.	EVEN Number followed by Folio Number registered with the Company For example if folio number is 001*** and EVEN is 101456 then user ID is 101456001***.

5. Password details for Shareholders other than Individual Shareholders are given below:

a) If you are already registered for e-Voting, then you can use your existing password to login and cast your vote.

b) If you are using NSDL e-Voting system for the first time, you will need to retrieve the 'initial password' which was communicated to you. Once you retrieve your 'initial password', you need to enter the 'initial password' and the system will force you to change your password.

c) How to retrieve your 'initial password'?

(i) If your email ID is registered in your demat account or with the Company, your 'initial password' is communicated to you on your email ID. Trace the email sent to you from NSDL from your mailbox. Open the email and open the attachment i.e. a .pdf file. Open the .pdf file. The password to open the .pdf file is your 8 digit client ID for NSDL account, last 8 digits of client ID for CDSL account or folio number for shares held in physical form. The .pdf file contains your 'User ID' and your 'initial password'.

(ii) If your email ID is not registered, please follow steps mentioned below in process for those Shareholders whose email IDs are not registered.

6. If you are unable to retrieve or have not received the "Initial password" or have forgotten your password:

a) Click on **"Forgot User Details/ Password?"** (If you are holding shares in your demat account with NSDL or CDSL) option available on www.evoting.nsdl.com.

b) **"Physical User Reset Password?"** (If you are holding shares in physical mode) option available on www.evoting.nsdl.com.

c) If you are still unable to get the password by aforesaid two options, you can send a request at evoting@nsdl.co.in mentioning your demat account number/ folio number, your PAN, your name and your registered address etc.

- d) Members can also use the OTP (One Time Password) based login for casting the votes on the e-Voting system of NSDL.
7. After entering your password, tick on Agree to “Terms and Conditions” by selecting on the check box.
8. Now, you will have to click on “Login” button.
9. After you click on the “Login” button, Home page of e-Voting will open.

Step 2: Cast your vote electronically and join General Meeting on NSDL e-Voting system. How to cast your vote electronically and join General Meeting on NSDL e-Voting system?

How to cast your vote electronically and join General Meeting on NSDL e-Voting system?

1. After successful login at Step 1, you will be able to see all the companies “EVEN” in which you are holding shares and whose voting cycle and General Meeting is in active status.
2. Select “EVEN” of company for which you wish to cast your vote during the remote e-Voting period and casting your vote during the General Meeting. For joining virtual meeting, you need to click on “VC/OAVM” link placed under “Join General Meeting”.
3. Now you are ready for e-Voting as the Voting page opens.
4. Cast your vote by selecting appropriate options i.e. assent or dissent, verify/modify the number of shares for which you wish to cast your vote and click on “Submit” and also “Confirm” when prompted.
5. Upon confirmation, the message “Vote cast successfully” will be displayed.
6. You can also take the printout of the votes cast by you by clicking on the print option on the confirmation page.
7. Once you confirm your vote on the resolution, you will not be allowed to modify your vote.

General Guidelines for Shareholders

- I) Institutional Shareholders (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/ JPG Format) of the relevant Board Resolution/ Authority letter etc. with attested specimen signature of the duly authorized signatory (ies) who are authorized to vote, to the Scrutinizer by e-mail to mrchechi@yahoo.com with a copy marked to evoting@nsdl.co.in.
- II) It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential. Login to the e-Voting website will be disabled upon five unsuccessful attempts to key in the correct password. In such an event, you will need to go through the “Forgot User Details/ Password?” or “Physical User Reset Password?” option available on www.evoting.nsdl.com to reset the password.
- III) In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-Voting user manual for Shareholders available at the download section of www.evoting.nsdl.com or call on toll free no.: 1800 1020 990 and 1800 22 44 30 or send a request to NSDL at evoting@nsdl.co.in.
- IV) **Process for those Shareholders whose email ID are not registered with the depositories for procuring user id and password and registration of email IDs for e-Voting for the resolutions set out in this notice and for obtaining Notice and Annual Report:**
 - a) In case shares are held in physical mode please provide Folio No., Name of Shareholder, scanned copy of the

share certificate (front and back), PAN (self-attested scanned copy of PAN card), AADHAR (self-attested scanned copy of Aadhar Card) by email to cs@ajoonibiotech.com.

- b) In case shares are held in demat mode, please provide DPID-CLID (16-digit DPID + CLID or 16 digit beneficiary ID), Name, client master or copy of Consolidated Account statement, PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) to cs@ajoonibiotech.com. If you are an Individual Shareholders holding securities in demat mode, you are requested to refer to the login method explained at **step 1 (A) i.e. Login method for e-Voting and joining virtual meeting for Individual Shareholders holding securities in demat mode.**
- c) Alternatively Shareholders/ Members may send a request to evoting@nsdl.co.in for procuring user id and password for e-Voting by providing above mentioned documents.
- d) In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual Shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are required to update their mobile number and email ID correctly in their demat account in order to access e-Voting facility.

FOR HELP IN CONNECTION WITH VOTING BY ELECTRONIC MEANS OR FOR PARTICIPATING IN THE AGM THROUGH VC:

Members can directly contact NSDL, 4th Floor, 'A' Wing, Trade World, Kamala Mills Compound, Senapati Bapat Marg, Lower Parel, Mumbai- 400 013. email ID: evoting@nsdl.co.in, Toll free no.: 1800 1020 990 and 1800 22 44 30. Members may also write to the Company Secretary at the email ID: cs@ajoonibiotech.com.

PROCEDURE TO RAISE QUESTIONS/ SEEK CLARIFICATIONS WITH RESPECT TO ANNUAL REPORT

- a) As the AGM is being conducted through VC, Members are encouraged to express their views/ send their queries in advance mentioning their name, DP ID and Client ID/ Folio No., e-mail ID, mobile number at cs@ajoonibiotech.com to enable smooth conduct of proceedings at the AGM. Questions/ Queries received by the Company on or before **Tuesday, September 23, 2025** on the aforementioned e-mail id shall only be considered and responded to during the AGM.
- b) Members who would like to express their views or ask questions during the AGM may register themselves as a speaker by sending their request from their registered email address mentioning their Name, DP ID and Client ID/ Folio Number, PAN, Mobile Number at cs@ajoonibiotech.com on or before **Tuesday, September 23, 2025**. Those Members who have registered themselves as a Speaker will only be allowed to express their views/ ask questions during the AGM.
- c) The Company reserves the right to restrict the number of questions and number of speakers, depending on the availability of time for the AGM.

INSTRUCTIONS FOR SHAREHOLDERS ATTENDING THE AGM THROUGH VC/OAVM ARE AS UNDER:

- 1) Member will be provided with a facility to attend the AGM through VC/OAVM through the NSDL e-Voting system. Members may access by following the steps mentioned above for Access to NSDL e-Voting system. After successful login, you can see link of "VC/OAVM link" placed under "Join General meeting" menu against company name. You are requested to click on VC/OAVM link placed under Join General Meeting menu. The link for VC/OAVM will be available in Shareholder/Member login where the EVEN of Company will be displayed. Please note that the members who do not have the User ID and Password for e-Voting or have forgotten the User ID and Password may retrieve the same by following the remote e-Voting instructions mentioned in the notice to avoid last minute rush.

- 2) Members are encouraged to join the Meeting through Laptops for better experience.
- 3) Further Members will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.
- 4) Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.
- 5) Share holders who would like to express their views/have questions may send their questions in advance mentioning their name demat account number/folio number, email id, mobile number at cs@ajoonibiotech.com. The same will be replied by the company suitably.
- 6) Those shareholders who have registered themselves as a speaker will only be allowed to express their views/ask questions during the meeting.

THE INSTRUCTIONS FOR MEMBERS FOR e-VOTING ON THE DAY OF THE AGM ARE AS UNDER: -

- 1) The procedure for e-Voting on the day of the AGM is same as the instructions mentioned above for remote e-voting.
- 2) Only those Members/ shareholders, who will be present in the AGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system in the AGM.
- 3) Members who have voted through Remote e-Voting will be eligible to attend the AGM. However, they will not be eligible to vote at the AGM.
- 4) The details of the person who may be contacted for any grievances connected with the facility for e-Voting on the day of the AGM shall be the same person mentioned for Remote e-voting.

Date: 29/08/2025

Place: Mohali

**By Order of the Board of Directors
For Ajooni Biotech Limited**

**Sd/-
Swati Vijan
F13627
Company Secretary**

Annexure

Details of the Director seeking appointment/ re-appointment as required under Regulation 36(3) of SEBI(LODR) Regulations, 2015 and Secretarial Standards issued by Institute of Company Secretaries of India:-

S.NO.	PARTICULARS	INFORMATION
1	Agenda Item No.	2
2	Name	Partek Singh
3	Date of Birth	02/03/1990
4	Date of Appointment on the Board	30/06/2017
5	DIN	07864006
6	Nationality	Indian
7	Qualification	He holds a Bachelor's Degree in Commerce from Punjabi University, Patiala.
8	Brief Profile/ Expertise	He looks after day-to-day routine operational activities of our Company and formulation of business policies, strategies etc. having extensive experience in project management and associated domains.
	Terms & Conditions of appointment or reappointment	Retire by rotation and being eligible, offers himself, for re-appointment as a Director
9	Directorship held in other companies	Nil
10	Listed entities from which he/she has resigned as Director in past three years	Nil
11	Chairman/ Member of The Committee of the Board Of the Other Companies in which he/she is a director	Nil
12	Equity Shares held in the Company as on 31/03/2025	100
13	Disclosure of relationships between directors inter-se	Not related to any director